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ABSTRACT

Author: Petell, Christopher J. PhD
Institution: Purdue University
Degree Received: December 2017
Title: Mechanisms Regulating DNA Methyltransferases
Committee Chair: Dr. Humaira Gowher

The expression of specific genes that are regulated by transcription factors and
epigenetic modifications is critical for normal cellular functioning and homeostasis. DNA
methylation is an epigenetic modification that in mammals is crucial for the regulation of
gene expression in a specific cell type. Aberrant loss or gain of DNA methylation is linked
to cancer and several epigenetic disorders. DNA methylation is established by the de novo
DNA methyltransferases Dnmt3a and Dnmt3b; however, the mechanisms underlying their
target specificity remain to be fully understood. Dnmt3a and Dnmt3b can be regulated
through interactions with other proteins, including histone modifications, and by their
catalytic properties. The N-terminal domain of Dnmt3a interacts with chromatin and can
potentially regulate its specific activity. Enzymatic studies have shown that the ADD
domain of Dnmt3a autoinhibits its catalytic activity, which is relieved by binding of the
ADD domain to an unmethylated H3K4 histone peptide. Using embryonic stem cell
differentiation as a model system to study the regulation of Dnmt3a and Dnmt3b activity,
we show that Lsd1-mediated H3K4 demethylation acts as an epigenetic switch to activate
Dnmt3a specifically at the enhancers of pluripotency genes during differentiation. We
show that Dnmt3b had only a minor role at these sites, in agreement with the previously
published work showing distinct functions of these enzymes. Dnmt3a and Dnmt3b activity
is involved in the development of several cancers, including Acute Myeloid Leukemia

xv
(AML). A specific mutation in the catalytic domain of Dnmt3a is highly prevalent in AML.
Our studies show that this mutation (R878H) results in the loss of cooperative activity of
the enzyme at multiple target sites on the DNA. To support these studies, we also developed
an assay to quantify DNA methylation using the methylation dependent restriction enzyme
MspJI to cleave DNA that is then used as a template for a quantitative PCR reaction. Use
of MspJI increased the accuracy of this method as compared to using a traditional,
methylation sensitive enzyme, HpaII. These studies contribute to our understanding of the
basis of Dnmt3 target specificity and provide a framework to explain the basis of diseases
with aberrant DNA methylation. They also provide both a basis to determine new
therapeutic strategies and to evaluate DNA methylation as a biomarker for various disease
states.
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CHAPTER 1: INTRODUCTION

1.1

The genome
The basic structural unit of chromatin is the nucleosome, which constitutes

approximately 147 bp of DNA, wrapped around an octamer of histone proteins forming a
bead on a string structure. (1, 2). Together with proteins, such as the linker histone H1,
nucleosomes can be compacted into increasing sizes of fiber-like structures that can be
further compacted during cell division (3, 4). The information content of DNA lies both
in the genes that encode a protein or non-coding RNA, as well as in the intergenic
sequences that control gene expression. The transcription of a gene is controlled by a
proximally placed region at the 5’ end called a promoter, which serves as a binding site
for the transcription apparatus (5). In complex genomes, genes include coding exons and
non-coding introns within the gene body. The transcription at a large number of genes is
additionally controlled by distal regulatory elements known as enhancers that activate
transcription in a distance and orientation independent manner. (6, 7). This complex
arrangement of gene elements in chromatin permits multiple levels of regulation of gene
expression.
1.2

Regulation of transcription
Gene expression is regulated by transcription factors that interact with specific

sequences at the promoter and enhancer elements (8, 9). The binding of these
transcription factors to specific promoters and enhancers drives cell-specific transcription
patterns (10, 11). Transcription factors interact with RNA polymerase II, which
transcribes the gene into RNA, to form a transcription initiation complex (12).
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Phosphorylation at specific sites of the regulatory CTD of RNA polymerase II promote
initiation and elongation of transcription (13, 14). The elongating RNA is cotranscriptionally acted on by several complexes that stabilize and splice the nascent premRNA transcript (15). Dissociation of the elongation complex from the DNA by the
activity of one of two complexes results in termination of transcription (16). These
mechanisms regulate or influence transcription; however, additional factors also effect
gene regulation.
1.3

Epigenetic regulation of gene expression
Epigenetic regulators include modifications of the DNA, histone variants, histone

modifications, non-coding RNAs, and genome topology (17, 18). DNA can be directly
modified without altering the sequence by the deposition of a methyl group onto cytosine
(19, 20). Histone variants are specialized histones that can be incorporated in place of
common histones and result in increased DNA accessibility for DNA binding factors and
transcription machinery (21, 22). Further, the position and density of histones in a gene
element affects sequence accessibility (23). Histones have disordered N-terminal tails
that can carry modifications that associate with active and repressed gene states (24).
Another level of epigenetic regulation are non-coding RNAs, whose position and
orientation can affect expression of adjacent genes (25-27). Genome topology influences
the spatial position of the regulatory elements of genes, such as enhancers and promoters,
that adopt a looped architecture and support gene activation (28-30).
Transcriptionally active euchromatin or repressive heterochromatin associate with
distinct chromatin modification states. DNA methylation is associated with repression
when at the regulatory elements, but is correlated with transcription when found in the
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gene body (31, 32). Replacement of canonical histones with histone variants, such as
H3.3 or H2A.Z, destabilize the nucleosome thus promoting DNA accessibility for the
transcription apparatus (33). Histone modifications and the genic context of those
modifications are critical determinants for gene state and are referred to as the histone
code (34). In this code, modification of multiple lysine residues on H3 and H4 with
acetyl moieties is activating, because charge repulsion of adjacent nucleosomes generates
an open chromatin structure (35). Methylation of lysine residues of histone H3 including
H3K4, H3K9, H3K27, H3K79, and H3K36 associate with active or repressed states
depending on context (36, 37). Multiple histone modifications can be found in
combination on a histone tail, with specific groups of modifications associating with
specific gene states.
1.4

Epigenetic modifications at genomic elements
To understand the relationship between epigenetic modifications and the

transcriptional state of a gene, it is critical to consider their genomic location. In the gene
body, active transcription is associated with methylation of H3K36 and H3K79, DNA
methylation, and enrichment of the variant H3.3; conversely, absence of these marks and
presence of H3K9 methylation is associated with repression (38-41). At the promoter,
marks correlated to active transcription include enrichment of the variant H2A.Z, histone
acetylation at multiple lysine residues, and H3K4 trimethylation; for a repressed gene,
promoters carry H3K9 and H3K27 trimethylation as well as DNA methylation (38-42).
Enhancers have several chromatin states- active, poised, primed, and repressed - that
have their own defining suites of epigenetic modifications (43, 44). Active enhancers
carry H3K4me1, H3K27ac, are enriched for histone variants H2A.Z, may include H3.3,
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and form a loop with promoters to promote transcription (45-47). In a primed state,
enhancers carry H3K4me1, may also have H2A.Z, and possibly H3.3; if the enhancers
are being initiated from an inactive state then 5-hydroxymethylation of cytosine can be
present (46, 48, 49). In embryonic stem cells, a class of “poised” enhancers is present that
have H3K4me1 and H3K27me3, histone variants H2A.Z, can have H3.3, and may be
looped with their target promoters (48-50). Lastly, repressed enhancers lack the active
histone marks and histone variants, present H3K9me3, and are not looped with their
promoters (49, 51, 52). These diverse chromatin states are critical for indicating what
impact the enhancer is having on gene expression.
1.5

Chromatin modifying factors at enhancers
Enhancers predominantly enrich for chromatin modifications that include

H3K4me1, H3K27me3 and H3K27ac together with histone variant H2A.Z. The histone
methyltransferase MLL4 in the MLL4 COMPASS-like complex deposits H3K4me1 at
enhancers and the demethylase UTX in this complex is critical for the removal of
H3K27me3 (53-56). Because the MLL4 COMPASS-like complex deposits H3K4me1
and removes H3K27me3, this complex is associated with primed and active enhancers, as
well as with poised enhancers in embryonic stem cells (57, 58). The histone
acetyltransferase P300, or CBP, deposits H3K27 acetylation at enhancers, and is found at
potentially active enhancers (59-61). The nucleosome remodeling complexes, BAF,
INO80, and TIP60/P400, affect nucleosome occupancy at enhancers (62, 63). BAF, or
mSWI/SNF, uses ATP-dependent remodeling activity of the subunit BRG1 or hBRM to
translocate or eject nucleosomes (64, 65). The ATP-dependent subunit INO80 exchanges
H2A with H2A.Z and can translocate nucleosomes to effect nucleosome density (66, 67).
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Lastly, the P400 subunit of the TIP60/P400 complex is able to reposition nucleosomes
and deposit H2A.Z (63, 68). These remodeling activities facilitate the binding of DNA
binding factors to their specific sites (21, 22). The mediator and cohesin complexes
permit enhancer-mediated gene activation by forming enhancer-promoter loops (30, 6971). The mediator complex interacts with transcription factors and RNA polymerase II
to facilitate transcription (72, 73). The cohesin complex, which is loaded onto chromatin
by NIPBL, forms a ring-like structure that holds together two distant genomic sites (7476). These complexes generate a chromatin structure where the enhancer interacts with
its target promoter to augment gene expression.
1.5.1 PRC2 and Mi2-NuRD activites regulate enhancer repression
A repressive chromatin environment is established primarily by two complexes
that alter histone modifications or nucleosome density. The H3K27 methyltransferase
EZH2 of the PRC2 complex deposits H3K27 methylation at poised enhancers in
embryonic stem cells (48, 77, 78). The major repressive complex is the Mi2-NuRD
complex, which has both nucleosome remodeling activity and histone deacetylase
activity (79-81). In stem cells, the remodeling activity requires the ATP-dependent
remodeler CHD4 or Mi-2β but the complex can include CHD3 or CHD5, although CHD5
is specific to the testis and central nervous system (82-85). The deacetylases HDAC1
and HDAC2 remove H3K27ac at the enhancers and from other lysine residues (86, 87).
The non-catalytic protein MBD3 binds to DNA independent of methylation state and
knockout of this protein results in differentiation defects (88-90). The MTA1/2/3 and
p66α/β (GATA2a/b) subunits are interchangeable proteins that bind to DNA and may
affect recruitment, though only MTA1, MTA2, and p66α or GATA2a show embryonic
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defects (18, 91, 92). Lastly, the Rbbp4 or 7 subunits can be interchanged and have a
structural role as well as binding to H3/H4 (91, 93, 94). While the activity of the PRC2
complex is specific to a certain class of enhancer in embryonic stem cells, the Mi2/NuRD
complex has a more significant impact on gene repression during differentiation. The
reason for this is that the demethylase Lsd1 can associate with Mi2-NuRD complexes and
is necessary for enhancer silencing by removal of H3K4me1 (51, 95, 96).
1.5.2 Lsd1: activity and interactions
Lsd1 has H3K4 and H3K9 demethylation activity that is dependent on
deacetylation of histone substrates and the cofactor FAD (97, 98). The overexpression of
Lsd1 in various cancers and the fact that it uses FAD rather than α-ketoglutarate, which is
commonly used by other demethylases, means that Lsd1 activity can be inhibited by
using MAO inhibitors such as pargyline and tranylcypromine that form FAD-inhibitor
adducts (99). Pargyline or tranylcypromine treatment of stem cells results in the retention
of H3K4me1 and an active enhancer state at pluripotency genes, similar to cells with
Lsd1 knocked down or catalytically dead Lsd1 (51). The Lsd1 and the Mi2-NuRD
subunits HDAC1/2 can interact with the CoREST complex while the HDAC1/2 can also
interact with the REST complex; however, neither the CoREST nor REST complexes are
found at the enhancers of pluripotency genes in embryonic stem cells (51, 100). Further,
Lsd1 is able to interact with Oct4, suggesting a possible recruitment mechanism for Lsd1,
and therefore the Lsd1/Mi2-NuRD complex (101, 102).
1.6

DNA methylation
DNA methylation is an epigenetic modification where a methyl group is

deposited at the N4 or C5 of cytosine or the N6 of adenine (20). A set of motifs highly
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conserved from bacteria to humans is required for the activity of DNA methyltransferases
to transfer the methyl group from S-adenosylmethionine (SAM or Adomet) to DNA (103,
104). DNA methylation has multiple biological roles. In bacteria, a restrictionmodification system consisting of a restriction endonuclease and a methyltransferase is
used as a defense mechanism (105). The restriction enzyme cleaves the exogenous
sources of DNA, such as viruses, that are not protected by DNA methylation like the host
genome (106-108). In metazoans, DNA methylation is essential for cell identity and
development (109, 110). DNA methylation in mammals is largely present at the CpG
dinucleotide (111, 112). It is established by the de novo methyltransferases Dnmt3a and
Dnmt3b and maintained through cell division by the maintenance methyltransferase
Dnmt1 (20, 113-115). Dnmt1 copies the DNA methylation at the CpG dinucleotide from
the parent to daughter strand during replication (116, 117). Dnmt1, Dnmt3a, and Dnmt3b
are necessary for embryonic growth, as knockout of any of these genes is embryonic
lethal (115, 118). DNA methylation is required for maintenance of genome integrity and
for silencing of transposons and other repetitive sequences (119). Further, DNA
methylation is associated with gene repression when at regulatory elements and aberrant
methylation at these elements correlates with various cancers (114, 120, 121).
1.7

DNA methyltransferases
1.7.1 Catalytic mechanism of DNA methyltransferases
The conserved catalytic mechanism of DNA methyltransferases involves the

transfer of a methyl group to the C5 position of cytosine from SAM (122-125). A
catalytic cysteine in the active site performs a nucleophilic attack mediated by the
sulfhydryl group on the C6 carbon of cytosine. The cytosine is also protonated by a
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conserved glutamate at the N3 position, permitting the generation of a covalent enzymesubstrate intermediate. Subsequent deprotonation at the N3 position primes the C5 of the
cytosine to execute a nucleophilic attack on the methyl group of SAM. The DNA is
released from the catalytic site when the C5 is deprotonated, which results in the breaking
of the enzyme-substrate adduct.
1.7.2 Catalytic properties of mammalian DNA methyltransferases
While the mammalian DNA methyltransferases use the same catalytic
mechanism, they are structurally distinct and have unique catalytic parameters (126, 127).
Dnmt1 prefers to methylate DNA that is hemi-methylated, though it does possess limited
activity on unmethylated DNA (128-130). Additionally, Dnmt1 methylates DNA in a
processive manner, methylating DNA without completely dissociating between catalytic
cycles (131). These intrinsic catalytic properties are well-adapted for the role of Dnmt1 in
maintaining DNA methylation patterns post-replication.
The Dnmt3 enzymes act on both unmethylated and hemi-methylated DNA
substrates and have a bias towards CpG sites, but are able to methylate CpA or CpT sites
at low rates (132-135). Several studies have supported a mechanism for Dnmt3a that is
distributive and cooperative in its mode of action (136, 137). The cooperativity has been
attributed to the ability of Dnmt3a to form tetrameric and putatively higher-order
oligomeric structures via two interaction surfaces, a dimer and tetramer interface (138,
139). The critical nature of one of these interfaces is highlighted by a common mutation
found in Acute Myeloid Leukemia (AML) patients at the dimer interface that reduces the
catalytic activity of the mutant enzyme to 20% that of wild type (140, 141). By
comparison, there remains a paucity of information about Dnmt3b- some data support a
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processive mechanism, but do not address the impact of the highly conserved
multimerization interfaces and the related potential for cooperativity (142). Our
understanding of the catalytic properties of Dnmt3b has not developed apace with that of
Dnmt3a. This information is critical because mutations that affect catalytic properties in
Dnmt3b, as well as Dnmt3a, have been linked to several epigenetic diseases (143-145).
1.8 Regulation of Dnmt3a and Dnmt3b by interactions with other proteins
1.8.1 Interaction with DNA binding factors
Multiple mechanisms regulate de novo DNA methylation by Dnmt3a and Dnmt3b
at specific genomic regions and in various cell types (146). These include interactions
with DNA binding proteins, chromatin binding proteins, and post-translationally
modified histones (147-149). Site-specific DNA methylation occurs when transcription
factors interact with and recruit Dnmt3 enzymes to their binding sites; these include the
interaction of Dnmt3a with Myc and RP58, as well as the oncogenic fusion transcription
factor PML-RAR that occurs in acute promyelocytic leukemia (150-152). Thus, one
mechanism of site-specific DNA methylation is recruitment by DNA binding factors with
sequence specificity.
1.8.2 Interaction with chromatin modifying proteins
Multiple chromatin modifying proteins have been shown to interact with the
Dnmt3 proteins. At the repetitive elements, Dnmt3a and Dnmt3b interact with histone
tails with specific modifications and the chromatin binding protein HP1 thus enriching
DNA methylation at these genomic elements (115, 153, 154). The Dnmt3 enzymes can
also interact with the H3K9 methyltransferase G9a, which can recruit the Dnmt3 proteins
to specific genomic locations such as promoters (155-157). Another H3K9
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methyltransferase, Suv39h1, is able to interact with Dnmt3a and can contribute to the
development of a repressive chromatin environment (158). Both Dnmt3 enzymes are able
to interact with HDAC1 and HDAC2, which represents another possible mechanism to
recruit Dnmt3 proteins (151, 159, 160). In addition, interaction of Dnmt3a or Dnmt3b
with each other, or the catalytically inactive Dnmt3L, allsoterically activates both
enzymes (147, 161). Therefore, the Dnmt3 proteins can be recruited and activated
through interactions with chromatin binding proteins and other Dnmt3 family members.
1.8.3 Interaction with histone modifications
The Dnmt3 proteins have two chromatin interacting domains that have the
potential to regulate their activity on nucleosomal DNA (162). The PWWP domain of
Dnmt3b interacts with H3K36 methylation and is required for DNA methylation in gene
bodies (163, 164). An interaction between the ADD domain of Dnmt3a with H3K4me0
releases Dnmt3a from an autoinhibited conformation (165-168). This interaction has the
potential to explain the anti-correlation between DNA methylation and H3K4 methylated
regions (169, 170). Multiple enzymatic activities act at promoters, confounding the
evaluation of regulation of DNA methylation by H3K4 demethylation (171-174). In
contrast, at enhancer regions H3K4me1 is removed by Lsd1, and inhibition or
knockdown of Lsd1 results in retention of H3K4me1 (51). The potential functional
relationship between enhancer DNA methylation and the activity of Lsd1, as well as its
underlying mechanism, remains to be explored.
1.9 Model systems to investigate regulation of DNA methylation
Several model systems have been used to determine mechanisms regulating de
novo DNA methylation including bacteria, plants, and mammals. Tissue culture using
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cells derived from mammalian sources, particularly embryonic stem cells, have been used
as model systems to easily evaluate mechanisms of DNA methylation. Embryonic stem
cells can develop into any somatic cell derived from the embryo and are therefore
classified as pluripotent (175, 176). Embryonic stem cells can be maintained in a
pluripotent state by growth in the presence of the pro-pluripotency cytokine LIF and
induced to differentiate by withdrawal of LIF from the cell culture media (177).
Differentiation toward particular lineages can be supported by addition of specific agents
in the media; for example, addition of retinoic acid drives differentiation to ectodermal
lineages (177, 178). The process of differentiation can be monitored by morphological
changes in the tissue culture, where undifferentiated colonies of cells aggregate into
spherical embryoid bodies after induction of differentiation (179). The robust
differentiation protocols available and the ease of monitoring the differentiation process
make these cells a tractable model system.
To exploit enhancers, a model system is needed where the changes in histone
modifications and the effect of enhancer silencing on gene repression can be readily
followed. The transition from pluripotent to somatic cells is accompanied by large-scale
transcriptional and epigenetic changes that stably repress pluripotency genes and activate
lineage-specific genes (180, 181). During differentiation, it is critical that the enhancers
of pluripotency genes are silenced by the Lsd1/Mi2-NuRD complex to cause complete
repression of their genes (51, 79). Moreover, the expression of the Dnmt3 family
members is high in pluripotent stem cells and during early differentiation (115, 182, 183).
These factors make the repression of the enhancers of pluripotency genes during

12
differentiation an ideal model location to examine how H3K4 demethylation can regulate
DNA methyltransferase activity.
1.10 Quantification of DNA methylation
Several tools have been developed to detect and quantify DNA methylation,
depending on the need for the study. The benchmark method for quantifying DNA
methylation at cytosines utilizes sodium bisulfite conversion. In this method,
unmethylated cytosines are chemically converted to uracil thereby distinguishing them
from the methylated cytosines during detection by high-throughput sequencing (184186). Other methods use restriction enzymes coupled to a Southern blot or PCR that are
typically methylation sensitive, when the activity of the restriction enzyme is blocked by
methylation at its recognition site (187-190). These techniques can be further modified to
include bisulfite conversion to generate or destroy a unique cleavage site (191, 192). The
restriction enzyme-PCR method is easy, monitors multiple sites or samples, and has been
coupled to quantitative PCR (qPCR) for accurate analysis (193-195). Several methods
have been developed that employ qPCR coupled to methylation specific cleavage, where
the primers and/or probes used are selective for methylation state (196, 197). A family of
Mrr-like methylation dependent restriction enzymes has led to the discovery of new
enzymes that could be used to quantify DNA methylation (198). In contrast to
methylation sensitive enzymes, these enzymes cleave only when their recognition sites
are methylated. Previously, the methylation dependent McrBC complex has been tested
for its potential use when cleavage is coupled to qPCR with little success due to its
complex bipartite recognition sequence where half sites are separated by 50-1000 bp
(199). Therefore, the potential use for the new methylation dependent enzymes, including
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MspJI and FspJ1 among others, that have greater specificity and simpler recognition sites
than McrBC is yet to be evaluated. These enzymes could increase the accuracy of
quantifying DNA methylation by qPCR as a research tool or as a diagnostic biomarker.
1.11 Summary
1.11.1 Regulation of Dnmt3a by Lsd1 mediated H3K4me1 demethylation
We tested a mechanism whereby H3K4 demethylation can regulate DNA
methylation at pluripotency gene enhancers after inducing differentiation in embryonic
stem cells. Specifically, we hypothesized that Lsd1 catalyzed H3K4me1 demethylation is
the critical step that confers sites specific gain of DNA methylation post-induction of
differentiation. We first determined that Dnmt3a was the primary DNA methyltransferase
at a subset of six pluripotency gene enhancers. We showed that retention of H3K4me1
alone can preclude the normal gain of DNA methylation at these enhancers by the use of
Lsd1 and p300/CBP inhibitors. We isolated the effect of increased Oct4 expression in
Lsd1 inhibitor treated cells from that of the epigenetic regulators by using an Oct4
knockdown cell line to show that the epigenetic changes can directly regulate enhancer
DNA methylation. Further, our data indicated that the interaction of the ADD domain
with unmodified H3 tails is critical for this process. Last, our data suggested that Dnmt3a
is able to associate with a subset of Lsd1/Mi2-NuRD repressor complexes. Based on
these results, we propose a model for pluripotency gene enhancers where H3K4me1 acts
as an epigenetic switch to activate Dnmt3a activity via the interaction of the ADD
domain with the unmodified histone tail.
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1.11.2 Quantification of DNA methylation with MspJI cleaved DNA coupled to qPCR
We developed a novel method for quantifying DNA methylation using a
methylation dependent restriction enzyme. Because the commonly used restriction
enzymes are inhibited by DNA methylation, coupling them with qPCR to determine
DNA methylation changes can limit the range or accuracy of detection. For such
enzymes, the differences in template abundance may be at or near the threshold of
detection when low levels of DNA methylation are being analyzed. We hypothesized that
a methylation dependent enzyme would be more accurate for samples with low DNA
methylation content or gains when coupled to qPCR due to higher template abundance.
The Mrr-like enzyme family of enzymes are methylation dependent, and can be used to
test this hypothesis (198). In our study, we used the restriction enzyme HpaII, which is
blocked by cytosine methylation, and MspJI, which requires a modified cytosine. We
first showed that quantification of DNA cleaved with either enzyme is linear with respect
to DNA methylation under non-limiting template conditions, using DNA standards with
known percent methylation. We next provided evidence that quantification of MspJI
cleaved DNA is linear over a greater range of DNA concentrations compared to HpaII
when monitoring small gains of DNA methylation. We demonstrated that MspJI cleavage
coupled to qPCR is more accurate than HpaII cleaved DNA at the Sall4 enhancer by
comparison to bisulfite sequencing and DNA methylation standards. Lastly, we found
that the specificity of MspJI returned a more accurate analysis of DNA methylation at the
Oct4 enhancer than HpaII. Based on these data, we conclude that qPCR using DNA
cleaved by MspJI is more effective at monitoring small gains of DNA methylation over a
wider range of detection and with greater accuracy than DNA cleaved by HpaII.
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1.11.3 Significance
Taken together, these studies delineate the regulatory mechanisms of DNA
methylation at specific genomic sites, as well as a method to evaluate the deposition of
DNA methylation at those sites. Our study of the regulation of DNA methylation at
enhancers represents a novel insight into the epigenetic mechanisms underlying Dnmt3a
activity and stable repression of pluripotency genes. Many cancer cell lines have aberrant
expression of pluripotency genes, highlighting the importance of stable repression of
these genes to maintain cell identity (200-202). Moreover, several studies have shown
that failure in the repression of genes that potentiate tumor development is frequently
accompanied with enhancer activation (203-207). In the long term, the repression
mechanism we delineated could help define new therapeutic targets and strategies to
establish normal DNA methylation profiles and/or the repression of pluripotency genes in
disease states. Our method using MspJI cleaved DNA as a template for qPCR to
determine DNA methylation changes can interrogate the connection between the cell
state and DNA methylation at specific sites in the genome. It can also be used to correlate
DNA methylation at a recognition motif with the presence of the corresponding DNA
binding factor, which is important considering that DNA methylation can effect
transcription factor binding (208). Further, this method is particularly suited to
examining DNA methylation dynamics at regions with low CpG content or when DNA is
limited. The diagnostic potential of our method is underscored by evidence that DNA
methylation at such regions is strongly correlated with disease states (209-212).
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Collectively, these studies advance the field of DNA methylation by describing a
new regulatory mechanism underlying the spatial and temporal specificity of the de novo
methyltransferases and a means of evaluating gains of DNA methylation.
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*CHAPTER 2: AN EPIGENETIC SWITCH REGULATES DE NOVO
DNA METHYLATION AT A SUBSET OF PLURIPOTENCY GENE
ENHANCERS DURING EMBRYONIC STEM CELL
DIFFERENTIATION

*Formatted for dissertation from the article published in Nucleic Acids Research:
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2.2 Abstract
Coordinated regulation of gene expression that involves activation of lineage
specific genes and repression of pluripotency genes drives differentiation of embryonic
stem cells (ESC). For complete repression of pluripotency genes during ESC
differentiation, chromatin at their enhancers is silenced by the activity of the Lsd1Mi2/NuRD complex. The mechanism/s that regulate DNA methylation at these enhancers
are largely unknown. Here, we investigated the activity of the Lsd1-Mi2/NuRD complex
as a dynamic regulatory switch that induces the local interaction of histone tails with the
Dnmt3 ATRX-DNMT3-DNMT3L (ADD) domain, thus promoting DNA methylation at
the enhancers of a subset of pluripotency genes. This is supported by previous structural
studies showing a specific interaction between Dnmt3-ADD domain with H3K4
unmethylated histone tails that is disrupted by histone H3K4 methylation and histone
acetylation. Our data suggests that Dnmt3a activity is triggered by Lsd1-Mi2/NuRD mediated histone deacetylation and demethylation at these pluripotency gene enhancers
when they are inactivated during mouse ESC differentiation. Using Dnmt3 knockout
ESCs and the inhibitors of Lsd1 and P300 histone modifying enzymes during
differentiation of E14Tg2A and ZHBTc4 ESCs, our study systematically reveals this
mechanism and establishes that Dnmt3a is both reader and effector of the epigenetic state
at these target sites.
2.3 Introduction
DNA methylation is established by de novo methyltransferases (MTases) Dnmt3a
and 3b and is maintained through replication by Dnmt1 that copies the methylation
pattern from parent to daughter strand (20, 114). In contrast to maintenance methylation,
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the mechanism(s) that determine the specificity of de novo methylation are not
completely elucidated. Biochemical models proposed to explain the specificity of de novo
DNA methylation include the intrinsic ability of Dnmt3a and 3b to find their target
location (132, 137, 138, 142, 213) and the role of interacting factors such as DNA and
chromatin binding proteins (156, 157, 214, 215). Further, both direct and indirect
relationships have been identified between histone tail modifications and DNA
methylation (216-220). Interaction of HP1, a reader protein of histone H3K9
trimethylation (H3K9me3), with Dnmt3b leads to DNA methylation at pericentromeric
repeats in mouse embryonic stem cells (ESCs) (154). H3K9me3 also has been shown to
direct DNA methylation in plants (221) and in Neurospora (222). Structural and
biochemical studies have shown a direct interaction between the PHD-like ATRXDNMT3-DNMT3L (ADD) domain of de novo DNA MTases with an unmethylated
H3K4 histone peptide leading to the catalytic activation of Dnmt3a. This interaction was
blocked by H3K4 methylation and histone acetylation (165-168). These observations,
taken together with the genome-wide studies showing the specific presence of H3K4me3
at unmethylated CpG rich regulatory regions, led to a model in which H3K4 methylation
at regulatory elements protects them from DNA methylation by Dnmt3 enzymes (169,
170). In a recent study, this model was tested by mutating Dnmt3a to render its ADD
domain insensitive to H3K4 methylation. This Dnmt3a mutant was aberrantly targeted to
active H3K4me3 promoters of a subset of developmental genes that led to a decrease in
their gene expression and altered ESC differentiation (223). However, when the cell state
changes during ESC differentiation and gene repression is induced, whether histone
demethylation of H3K4 at some regulatory elements can locally recruit Dnmt3 enzymes
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has not been addressed. Therefore, we investigated a regulatory role of the interaction of
Dnmt3-ADD domain with demethylated histone tails in site-specific DNA methylation
during ESC differentiation.
In response to signals of differentiation, ESCs initiate global changes in gene
expression that are forged by alterations in the epigenetic state of the regulatory elements
of various cohorts of genes. Among these, pluripotency genes (PpGs) are downregulated
and at their promoters and enhancers aCquire a repressed chromatin state that includes
loss of histone H3K4 methylation and gain of DNA methylation. The interaction of
Dnmt3a with the G9A histone methyltransferase has been shown to promote DNA
methylation at the PpG promoters post differentiation of ESCs (156, 157). However, little
is known about how DNA methylation is regulated at PpG enhancers. Histone H3K4me1
(monomethylation) and H3K27Ac (acetylation) are prototypical epigenetic modifications
for active enhancers (48). Compared to demethylation of histone H3K4me3 at promoters,
which is proposed to require the combined activity of Kdm5/Jarid family and Lsd1
demethylases, demethylation of H3K4me1 at enhancers only requires Lsd1 activity (51,
171-173). During differentiation of ESCs, Lsd1 associates with the Mi2/NuRD
deacetylase complex specifically at PpG enhancers. The activity of this repressive
complex is triggered by dissociation of the OSN (Oct4/Sox2/Nanog/HATp300)
coactivator complex resulting in enhancer repression by histone deacetylation and
demethylation, which is critical for PpG repression (51). Based on these observations we
speculated that deacetylated and demethylated H3K4 histone tails at PpG enhancers may
locally activate Dnmt3 enzymes via an interaction with their ADD domains, thus
conferring a unique regulatory potential to this series of epigenetic events. Our studies
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here provide evidence for the timing, location, and role of the interaction of the Dnmt3
ADD domain with demethylated histone tails in regulating site-specific DNA methylation
at a subset of PpG enhancers during ESC differentiation.
2.4 Materials and Methods
2.4.1 ESC Culture and Differentiation
E14Tg2A (WT) ESCs were maintained in media containing LIF and induced to
differentiate by LIF withdrawal and followed by retinoic acid addition (224). ZHBTc4
cells were maintained in media with LIF and induced to differentiate by simultaneous
withdrawal of LIF and addition of doxycycline (51). Treatment of the Lsd1 inhibitors
pargyline (3 mM) (Sigma, P8013), tranylcypromine TCP (1 mM) (Millipore, 616431),
and the p300 inhibitor C646 (400 nM) (Sigma, SML0002) were performed as described
(51). Low passage Dnmt3KO ESC were obtained from Dr. Taiping Chen, MD Anderson
and ZHBTc4 were obtained from Dr. Dana Levasseur, University of Iowa. Single (KO)
and double knockout (DKO) cells for Dnmt3a and/or Dnmt3b, as well as the transgenic
Myc-ADD and Myc-Vector expressing cell lines were grown and induced to differentiate
similar to E14Tg2A ESCs. For all experiments, ESC (all lines) were expanded by
passaging twice after which differentiation was induced. At various time points post
induction, a third of cells were harvested for preparation of DNA and RNA and rest were
crosslinked to prepare chromatin. For all experiments this procedure was repeated at least
2 times for sample collection.
2.4.2 Transgenic cell lines
The ADD domain of Dnmt3a was the same as defined (225). Standard molecular
cloning methods were used to generate Myc-tagged Dnmt3a-ADD constructs, and
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confirmed by DNA sequencing. The Lonza 4D-Nucleofector device was used to
generate the transgenic cell lines, per the manufacturer’s instructions. Transfected cells
were clonally propagated, and Western blots were used to determine the expression level
of the constructs with anti-cMyc antibody (Millipore, MABE282).
2.4.3 Chromatin Preparation
Cells were cross-linked with 1% formaldehyde in Cross-linking buffer (0.1 M
NaCl, 1 mM EDTA, 0.5 mM EGTA, and 50 mM HEPES pH 8) for 5 min., then quenched
by adding glycine to 150 mM. Nuclei were isolated by incubating in Triton-X100 Wash
Buffer (0.25% Triton X-100, 10 mM EDTA, 0.5 mM EGTA, 10 mM Tris pH 8.0) with
protease inhibitors (Roche, 11873580001) for 5 min. with agitation. Samples were pelleted
and resuspended in Salt Wash Buffer (0.2 M NaCl, 1 mM EDTA, 0.5 mM EGTA, 10 mM
Tris pH 8.0) and incubated as in the previous step. The nuclei were pelleted again and
resuspended in TEG Buffer (1 mM EDTA, 0.5 mM EGTA, 10 mM Tris pH 8.0) with
agitating as before. After pelleting, the nuclei were resuspended in Shearing buffer (TEG
with 100 mM NaCl, 0.1% Na-deoxycholate, and 0.5% IGEPAL). Chromatin was sonicated
in the nuclei with a Covaris E210 device, according to manufacturer’s protocols. Shearing
was confirmed by analyzing sonicated DNA on 1% agarose gels.
2.4.4 Chromatin Immunoprecipitation
ChIP was performed by first preparing an equal mixture of protein A magnetic
beads (Life Technologies, 10002D) and protein G magnetic beads (Life Technologies,
10004D). For Dnmt3a, M-280 Sheep anti-Mouse IgG magnetic beads were used (Life
Technologies, 11201D). The beads were washed three times with Blocking Solution (PBS
with 0.25% BSA) and mixing by inversion. The beads were resuspended in Blocking
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Solution with 8 µg of desired antibody and protease inhibitors. The mix of beads and
antibody was incubated overnight at 4°C with rotation. Antibodies used include: antiH3K4me1 (Active Motif, 39297), anti-H3K27Ac (Active Motif, 39133), and anti-Dnmt3a
(Active Motif, 39206). The next day the beads were washed twice with Blocking Solution.
Next, 8 µg sonicated chromatin was added to the prepared magnetic beads and incubated
overnight at 4°C with rotation. The following day, the ChIP samples were washed for 5
min. once with each of the following buffers, in order: Low Salt Wash Buffer (0.1% SDS,
1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl, pH 8.1), High Salt Wash
Buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 500 mM NaCl, 20 mM Tris-HCl, pH
8.1), LiCl Wash Buffer (250 mM LiCl, 1% IGEPAL-CA630, 1% Na-Deoxycholate, 1 mM
EDTA, 10 mM Tris-HCl, pH 8.1) and 1xTE buffer (10 mM Tris-HCl, 1 mM EDTA, pH
8.0). Samples were eluted by adding Elution Buffer (1% SDS, 10 mM EDTA, 50 mM TrisHCl, pH 8.0) and incubating at 65°C for 30 min. with shaking. For the Myc-tagged
constructs, 40 µL of anti-Myc agarose resin was used per ChIP and allowed to incubate
with 8 µg chromatin overnight (Sigma, A7470). Washes were performed using buffers
described above, and the samples were eluted by rotating twice with Elution Buffer
(1%SDS, 100mM NaHCO3) for 15 min. at 12 rpm at RT. Input samples was processed in
parallel to the IP samples. Cross-links were reversed for input and IP samples by addition
of NaCl (200 mM), and incubation at 65°C overnight. The samples were treated with
RNase (Roche, 11119915001) and Proteinase K (Worthington, LS004222) and purified.
DNA samples were quantified using PicoGreen (Life Technologies, P11495) using a
NanoDrop 3300 fluorospectrometer. Quantitative PCR was then performed using identical
amounts of IN (input) and IP (immunoprecipitated sample) DNA. Percent input was
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calculated as follows: 2^( Cq(IN)-Cq(IP))X100. To illustrate the change in enrichment post
differentiation, the resulting percent enrichment was then normalized to UD which was set
to 1. For Myc-ADD ChIP, the percent enrichment for the ADD domain was determined by
subtracting the percent enrichment obtained for the vector control. For ZHBTc4 cells,
sample were normalized to the negative control region. See Table 2.4 for primers used.
2.4.5 DNA Methylation-Dependent qPCR Assay (MD-qPCR)
Genomic DNA was harvested using a standard phenol:chloroform isolation,
followed by ethanol precipitation. DNA from various samples was digested initially with
CviQI (NEB, R0639L) overnight at 25°C. Purified samples were subjected to digestion
by MspJI (NEB, R0166L) overnight at 37°C. Digested DNA was purified and quantified
by PicoGreen according to manufacturer’s protocol (Life Technologies, P11495) using
the NanoDrop 3300 fluorospectrometer. Quantitative PCR was performed by using equal
amount of DNA for each sample. Change in DNA methylation is represented by relative
fold change in the Cq values as follows: 2^[Cq(U)-Cq(I)], where Cq(U) is the Cq for the
undifferentiated (ESC) sample, and Cq(I) represents a sample from a given time point
post differentiation. Cq is the quantification cycle as calculated by the Biorad CFX
Manager 3.1 based on the MIQE guidelines (226). The primers used DNA methylationdependent qPCR analysis were the same used for ChIP. Standard deviations represent at
least 2 technical and 2 biological replicates.
2.4.6 Quantitative RT-PCR
RNA was isolated by using TRIzol (Invitrogen, 15596026) according to
manufacturer’s protocol, and purified after DNAse treatment (Roche, 04716728001). RTqPCR was performed by using Verso One-Step RT-qPCR kits (Thermo Scientific, AB-
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4104A). The data analysis was performed by calculating delta Cq normalized to Gapdh
expression and represented as change relative to undifferentiated (ESC) expression,
which was set to 0. Cq is the quantification cycle as calculated by the Biorad CFX
Manager 3.1 based on the MIQE guidelines (226). Change in expression is reported in a
log2 scale and the average data for 8 PpG is reported for Figure 2.1, 2.4 and 2.6. Standard
deviations represent at least 2 technical and 2 biological replicates. The variance in
average data is represented by SEM with n=8. The SD, SEM determination and P-Value
were calculated using GraphPad Prism using paired Student’s paired T-test. See Table 2.4
for primers used.
2.4.7 Microscopy
Alkaline phosphatase staining was performed using AP staining kit (Sigma,
AB0300) using manufacturers protocol. AP staining was imaged by using a Zeiss
microscope at 20X objective. Immunofluorescence was performed according to Whyte et
al., 2012 (51). Antibodies used for immunofluorescence include: SSEA-1 (Millipore,
MAB430) 1:2000 and AlexaFluor 555 nm (Life Technologies, A21422) 1:1000.
Brightfield imaging was done with a Nikon Ts microscope with a 20X objective.
2.4.8 Bisulfite Sequencing
Bisulfite sequencing was performed by using the EpiTect Fast Bisulfite
Conversion Kit (Qiagen, 59802) according to the manufacturer’s protocol. Bisulfiteconverted DNA was amplified using nested primers and published methods (227).
Products from the inner PCR were gel purified (Qiagen, 28704) and used to generate a
barcoded library for Mi-Seq. Barcoded amplicons for each region was purified and
pooled to a final concentration of 8 pM. Illumina MiSeq 500 cycle run generated paired-
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end 250 base reads. The reads were then mapped by Bowtie2 and analyzed by Bismark
for DNA methylation. Instances of methylated and unmethylated CpG were quantified
and summed to an overall percent methylation for each enhancer region with standard
deviations. An average percent methylation for all the enhancers was computed and the
variance is represented by SEM with n=6. See Table 2.2 for number of reads for each
sample and site, and Table 2.3 for the percent CpG methylation by region for each
sample. See Table 2.4 for primers used for bisulfite sequencing.
2.4.9 ChIP- Western and Co-immunoprecipitation
For the ChIP-Western, cross-linked chromatin was processed as described in the
ChIP protocol. For the detection of proteins in ChIP samples, elution was performed with
Laemmli’s loading buffer. For co-immunoprecipitation, the nuclear extract was prepared
according to manufacturer’s protocol (Active Motif, 40010) except that DNase was added
for the release of chromatin-associated proteins. The co-IP was performed using
Dynabead M280 (Life Technologies, 11201D) conjugated with 5 µg antibody and with
50 µg of nuclear extract according to the manufacturer’s protocol. Antibodies used
include: anti-Dnmt3a (Active Motif, 39206), anti-Chd4 (Abcam, ab72418), anti-Hdac1
(Abcam, ab), anti-Lsd1 (Abcam, ab17721).
2.4.10 Western Blots
A standard Western blot was performed using the following antibodies and
dilutions: anti-Dnmt1, 1:1000 (Abcam, ab13537) and anti-Gapdh, 1:500 (Santa Cruz,
sc25778), and anti-Rabbit, 1:10,000 (Jackson Immunoresearch, 111-035-003) or antiMouse, 1:10,000 (Jackson Immunoresearch, 115-035-003. Chemiluminescence was
performed according to manufacturer’s protocol (Thermo-Fisher Scientific, 34076).
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2.4.11 Southern Blots
Isolated genomic DNA was subject to digestion with either HpaII (NEB, R0171L)
or MspI (NEB, R0106L). Equal amounts of various digested samples were loaded on an
agarose gel and processed for a Southern blot as described (228).
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Table 2.1: Number of CpGs detected to analyze DNA methylation.
The number of CpG sites detectable by either MD-qPCR or bisulfite-sequencing within the PpG enhancer
amplicon. For bisulfite sequencing amplicons are larger, permitting the analysis of a larger number of
CpGs. N/A: not applicable.
Enhancer

MD-qPCR

Bis-seq

No. of CpGs

Amplicon (bp)

No. of CpGs

Amplicon (bp)

Lefty1

0

N/A

4

~300

Lefty2

2

~100

6

~350

Sall4

2

~100

3

~400

Sox2

6

~100

10

~425

Trim28

3

~100

6

~450

Esrrb

2

~100

6

~475
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Table 2.2: MiSeq reads by samples and site.
The total number of reads from two MiSeq runs that were used for data presented in this study. The number
of reads have been separated by both the enhancer and samples; total reads per sample and site are also
shown, as well as the total reads.
Sample

Lefty1

Lefty2

Sall4

Sox2

Trim28

Esrrb

Total

ESC WT
D5 WT

182,369

92,150

55,809

15,766

50,174

99,115

495,383

30,944

117,496

95,646

55,715

14,404

47,039

361,244

D5 Prg WT

30,990

129,130

77,370

16,303

7,667

46,380

307,840

ESC ZHBTc4

280,508

211,622

107,896

50,576

72,721

64,162

787,485

D4 ZHBTc4
D4 Prg
ZHBTc4
ESC 3a KO

51,346

147,831

167,199

21,174

30,241

82,070

499,861

53,622

108,521

167,480

51,431

77,734

57,990

516,778

12,204

78,172

8,428

44,722

57,589

6,302

207,417

D5 3a KO

29,119

110,873

135,191

33,162

60,309

32,570

401,224

D9 3a KO

33,166

65,481

87,925

65,573

60,571

46,328

359,044

ESC 3b KO

2,304

97,579

9,333

86,794

1,521

6,357

203,888

D5 3b KO

68,010

146,683

96,171

71,576

57,862

54,044

494,346

D9 3b KO

43,763

150,704

125,688

109,436

30,519

50,326

510,436

ESC DKO

59,012

174,968

108,243

85,412

28,985

93,972

550,592

D5 DKO

42,466

121,553

123,405

18,897

9,306

78,651

394,278

D9 DKO
ESC Myc
Vector
D5 Myc Vector

43,853

158,435

111,125

59,582

21,344

36,271

430,610

3,306

94,824

16,655

7,490

39,499

6,494

168,268

2,199

75,226

5,195

6,947

5,286

25,597

120,450

D9 Myc Vector
ESC Myc 3a
ADD
D5 Myc 3a
ADD
D9 Myc 3a
ADD
ESC WT (for
C646)
D9 C646 WT
D9 C646 Prg
WT
D9 WT

2,805

102,073

15,941

6,792

6,123

9,520

143,254

15,951

46,301

20,476

4,939

5,532

12,633

105,832

2,478

65,623

23,373

20,958

4,673

17,546

134,651

6,272

56,106

13,838

6,719

19,199

17,763

119,897

21,454

83,693

51,235

10,641

47,886

27,869

242,778

19,381

99,958

26,503

9,058

78,031

57,596

290,527

6,975

61,267

26,759

29,394

78,329

58,500

261,224

24,108

111,302

75,894

5,133

6,994

41,443

264,874

D9 Prg WT

50,361

118,038

94,745

69,987

21,961

26,370

381,462

D5 TCP WT
D4 TCP
ZHBTc4
ESC ZHBTc4
(for C646)
D4 C646
ZHBTc4

7,946

1,193

52,576

30,471

1,160

12,275

105,621

704

32,117

1,483

2,758

10,537

4,432

52,031

92,131

46,528

47,896

29,197

3,083

8,954

227,789

90,026

38,727

45,211

28,096

1,569

7,211

210,840
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D4 C646 Prg
ZHBTc4
Total

68,618

33,790

33,456

36,889

2,470

2,036

177,259

1,378,391

2,977,964

2,028,145

1,091,588

913,279

1,137,816

9,527,183
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Table 2.3: Percent CpG methylation by enhancer.
The percent CpG methylation for all CpGs of each enhancer and the corresponding average of the six
enhancers and SEM that was plotted in the main figures. The average is that of all 6 enhancers, and the
SEM is derived from the error of standard deviation divided by the number of enhancers probed (n=6), as
described in Materials and methods. The data under Figure 2.1, 2.4, 2.6, 2.8, or 2.11 is used for the
averages shown in the respective figures in the main text.
Figure

Lefty1

Lefty2

Sall4

Sox2

Trim28

Esrrb

Average

Figure 1

Lefty1
13.32
±3.24
37.35
±3.93

Sall4
11.56
±1.96
41.75
±0.40
69.15
±0.35
3.00
±0.09
1.75
±0.02
8.53
±0.14
12.53
±0.05
18.93
±0.23
38.22
±0.12
1.28
±0.05
1.02
±0.12
4.53
±0.19

Sox2
2.25
±1.03
8.27
±0.04
27.37
±0.05
1.31
±0.05
1.36
±0.03
2.48
±0.01
1.73
±0.13
3.60
±0.01
15.29
±0.03
1.50
±0.37
1.53
±0.15
1.95
±0.16

Trim28
2.28
±0.29
22.18
±0.27
36.92
±0.42
1.86
±0.15
2.01
±0.13
7.83
±0.11
2.26
±0.09
2.54
±0.02
25.14
±1.54
1.09
±0.06
1.56
±0.06
9.15
±1.17

Esrrb
4.36
±1.07
23.10
±1.25
29.11
±1.40
1.85
±0.66
1.55
±0.07
3.38
±0.03
2.88
±0.61
2.34
±0.62
12.67
±0.61
1.11
±0.09
0.69
±0.09
6.71
±0.34

Average
5.86
±2.08
22.80
±5.71
35.79
±9.08
2.42
±0.58
2.07
±0.45
7.16
±2.43
5.31
±1.94
5.91
±2.58
22.12
±5.19
1.33
±0.20
1.03
±0.17
7.68
±2.87
Average
5.86
±2.08
22.80
±5.71
12.33
±4.68
7.36
±1.83

D5 DKO

0.90

D9 DKO

21.63
±0.07

Lefty2
1.41
±0.46
4.18
±0.66
8.36
±1.26
1.34
±0.05
1.34
±0.12
2.11
±0.26
1.64
±0.15
1.45
±0.17
5.25
±0.59
0.80
±0.07
0.50
±0.04
2.11
±0.16

Lefty1
13.32
±3.24
37.35
±3.93
20.89
±4.22

Lefty2
1.41
±0.46
4.18
±0.66
2.93
±0.03

Sall4
11.56
±1.96
41.75
±0.40
24.57
±0.56

Sox2
2.25
±1.03
8.27
±0.04
5.82
±0.20

Trim28
2.28
±0.29
22.18
±0.27
7.86
±0.25

Esrrb
4.36
±1.07
23.10
±1.25
11.95
±1.04

D5 TCP WT

13.43

3.05

12.00

7.71

3.50

4.48

Figure 3

Lefty1
11.92
±2.96
55.23
±6.68

Lefty2
2.07
±0.23
12.19
±079

Sall4
10.93
±2.50

Sox2
2.72
±0.84
36.72
±12.90

Trim28
2.29
±0.32
14.74
±1.47

Esrrb
3.74
±1.32

ESC WT
D5 WT
D9 WT
ESC 3a KO
D5 3a KO
D9 3a KO
ESC 3b KO
D5 3b KO
D9 3b KO
ESC DKO

Figure 2
ESC WT
D5 WT
D5 Prg WT

ESC ZHBTc4
D4 ZHBTc4

51.90
5.18
±0.14
4.39
±0.02
18.61
±0.09
10.84
±0.02
6.63
36.16
±0.09
2.21
±0.16

25.80

23.98

Average
5.30
±1.93
28.75
±7.09
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D4 Prg
ZHBTc4
D4 TCP
ZHBTc4

40.10
±4.10

7.53±
1.20

22.13±
3.20

25.77
±10.84

5.72
±1.09

12.26
±0.51

46.05

9.80

17.20

32.94

7.62

11.88

Figure 4
ESC WT (for
C646)

Lefty1
14.48
±0.03

D9 WT

51.90

Lefty2
1.67
±0.33
8.36
±1.26
10.98
±1.24
5.54
±0.44
6.70
±0.42
1.30
±0.02
12.19
±079
7.94
±0.03
3.17
±0.02
7.53
±1.20

Sall4
18.32
±0.49
69.15
±0.35
56.37
±0.23
26.15
±1.58
39.48
±0.26
6.40
±0.14

Sox2
4.52
±0.02
27.37
±0.05
22.39
±0.11
19.27
±1.58
14.11
±0.35
2.09
±0.03
36.72
±12.90
47.04
±0.25
19.46
±0.06
25.77
±10.84

Trim28
3.48
±0.09
36.92
±0.42
41.52
±0.67
11.81
±0.77
14.12
±0.21
1.68
±0.06
14.74
±1.47
13.88
±1.20
5.03
±.018
5.72
±1.09

Esrrb
7.13
±0.23
29.11
±1.40
22.40
±0.07
13.88
±0.84
16.47
±2.10
1.73
±0.11

Lefty2
2.45
±1.72
7.95
±1.30
-0.41
±0.44
6.33
±1.94

Sall4
9.49
±1.19
51.85
±5.16
6.49
±5.29
44.35
±5.3

Sox2
3.43
±0.57

Trim28
3.51
±0.41
23.83
±1.09
2.41
±0.30
22.13
±0.66

Esrrb
3.211
±1.02

D9 C646 Prg
WT

46.31
±0.02
34.44
±0.05

D9 Prg WT

39.60

ESC ZHBTc4
(for C646)

9.03
±0.03
55.23
±6.68
58.90
±0.07
29.40
±0.07
40.10
±4.10

D9 C646 WT

D4 ZHBTc4
D4 C646
ZHBTc4
D4 C646 Prg
ZHBTc4
D4 Prg
ZHBTc4
Figure 5
D5 Myc
Vector
D9 Myc
Vector
D5 Myc 3a
ADD
D9 Myc 3a
ADD

Lefty1
9.78
±0.03
43.14
±0.19
2.70
±0.07
34.53

25.80
17.35
±0.21
11.05
±0.21
22.13
±3.20

22.93
0.65
±0.06
17.05
±0.30

23.98
11.50
±0.64
6.93
±0.72
12.26
±0.51

24.66
0.75
±0.92
18.47
±1.04

15.73
±4.34
20.92
±6.25
Average
8.27
±2.59
35.79
±9.08
33.33
±6.76
18.51
±4.08
20.12
±5.46
3.70
±1.32
28.75
±7.09
26.10
±8.72
12.50
±4.12
15.73
±4.34
Average
5.31
±1.34
30.11
±6.74
2.10
±1.16
23.81
±5.33

33
Table 2.4: Primers used in this study.
Listing of PCR primers used for experiments in this study, separated by technique (5’ to 3’).
For Bisulfite PCR:
Primer
Trim28 out HSO3 F

ATGGATGTTTATGGAAGTAGTAGAAATA

Trim28 out HSO3 R

ACATCTAAATACTACCCAAAACCATTAC

Trim28 in HSO3 F

AATAGTTTAGGTTTTATTTTTTTTAAGATT

Trim28 in HSO3 R

AAACCATTACTTCAAAATAACTTTAAATTA

Sall4 out HSO3 F

AGGGATTATAATTTTTTGAGTTTTAGTTTATA

Sall4 out HSO3 R

AAAACCTCTAAAAAAACAATCAATACTCTTAA

Sall4 in HSO3 F

TATATAGAGAGGTTTAAATAAAGGGTTTTT

Sall4 in HSO3 R

TTTAAAACCACTAAACATATTAAAACATAA

Sox2 out HSO3 F

AGAAAATTGAGTTATTAAGGTAGTAATTATTT

Sox2 out HSO3 R

AAACCAAAAACCTTAACTACCAAACATAA

Sox2 HS03 in F

TAAAATTTTTATAGTTTTAATTGTTAAATA

Sox2 HSO3 in R

TATTATATCTAAAACCAACTAACAATATTAT

Lefty2 out HSO3 F

TTAGAAGTTTTTGGGGGAGAGGTTTGATTTA

Lefty2 out HSO3 R

TCAAAAATCATAACTCTTCCCACACCTCAAA

Lefty2 in HSO3 F

ATAATATGAGGGAGAGGTTTAGTTTTT

Lefty2 in HSO3 R

CACCTCAAACTCTATCTACTACTAACTTTA

Esrrb out HSO3 F

TTTGGAGAGGAAATATGTTAATTTTGAATA

Esrrb out HSO3 R

AAATCAACACACAAAATTCACTAAAAAAACA

Esrrb in HSO3 F

AATAGGGATTTTTTTTGGGATAGAAAT

Esrrb in HSO3 R

ATTCACTAAAAAAAAAAAAAATCTCAAA

Lefty1 out HSO3 F

AAATAAGGAGGTAGGGGTAGAGAATATTTGA

Lefty1 out HSO3 R

AAAAAACAATCTCCCTCCCACCTAACA

Lefty1 in HSO3 F

TTTAGAGGAGAAGTTAAGTTTAGTATAGAGAATA

Lefty1 in HSO3 R

ACACCTAATCAAACCCATTATACAAAAT

For Mi-Seq
Barcoding:

Primer

TS-Esrrb-F
TS-Esrrb-R
TS-Trim28-F
TS-Trim28-R
TS-Lefty2-F
TS-Lefty2-R
TS-Lefty1-F
TS-Lefty1-R

ACACTCTTTCCCTACACGACGCTCTTCCGATCTAATAGGGATTTTTT
TTGGGATAGAAAT
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTATTCACTAAAAA
AAAAAAAAATCTCAAA
ACACTCTTTCCCTACACGACGCTCTTCCGATCTAATAGTTTAGGTTT
TATTTTTTTTAAGATT
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTAAACCATTACTT
CAAAATAACTTTAAATTA
ACACTCTTTCCCTACACGACGCTCTTCCGATCTATAATATGAGGGA
GAGGTTTAGTTTTT
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCACCTCAAACTC
TATCTACTACTAACTTTA
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTTTAGAGGAGAAG
TTAAGTTTAGTATAGAGAATA
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTACACCTAATCAA
ACCCATTATACAAAAT
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TS-Sall4-F
TS-Sall4-R
TS-Sox2-F
TS-Sox2-R
i5-TS-DI-501
i5-TS-DI-502
i5-TS-DI-503
i5-TS-DI-504
i5-TS-DI-505
i7-TS-DI-701
i7-TS-DI-702
i7-TS-DI-703
i7-TS-DI-704
i7-TS-DI-705
i7-TS-DI-706
i7-TS-DI-707
i7-TS-DI-708
i7-TS-DI-709
i7-TS-DI-710

ACACTCTTTCCCTACACGACGCTCTTCCGATCTTATATAGAGAGGT
TTAAATAAAGGGTTTTT
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTTTAAAACCACT
AAACATATTAAAACATAA
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTAAAATTTTTATAG
TTTTAATTGTTAAATA
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTATTATATCTAA
AACCAACTAACAATATTAT
AATGATACGGCGACCACCGAGATCTACACTGAACCTTACACTCTTT
CCCTACACGAC
AATGATACGGCGACCACCGAGATCTACACTGCTAAGTACACTCTTT
CCCTACACGAC
AATGATACGGCGACCACCGAGATCTACACTGTTCTCTACACTCTTT
CCCTACACGAC
AATGATACGGCGACCACCGAGATCTACACTAAGACACACACTCTT
TCCCTACACGAC
AATGATACGGCGACCACCGAGATCTACACCTAATCGAACACTCTT
TCCCTACACGAC
CAAGCAGAAGACGGCATACGAGATATCACGACGTGACTGGAGTTC
AGACGTG
CAAGCAGAAGACGGCATACGAGATACAGTGGTGTGACTGGAGTTC
AGACGTG
CAAGCAGAAGACGGCATACGAGATCAGATCCAGTGACTGGAGTTC
AGACGTG
CAAGCAGAAGACGGCATACGAGATACAAACGGGTGACTGGAGTT
CAGACGTG
CAAGCAGAAGACGGCATACGAGATACCCAGCAGTGACTGGAGTTC
AGACGTG
CAAGCAGAAGACGGCATACGAGATAACCCCTCGTGACTGGAGTTC
AGACGTG
CAAGCAGAAGACGGCATACGAGATCCCAACCTGTGACTGGAGTTC
AGACGTG
CAAGCAGAAGACGGCATACGAGATCACCACACGTGACTGGAGTTC
AGACGTG
CAAGCAGAAGACGGCATACGAGATGAAACCCAGTGACTGGAGTTC
AGACGTG
CAAGCAGAAGACGGCATACGAGATTGTGACCAGTGACTGGAGTTC
AGACGTG

For RT-qPCR:
Dppa3 RT F

Primer
AAAAAGGCTCGAAGGAAATGAGTTT

Dppa3 RT R

TTTGATAATGGCAGAAAGTGCAGAG

Oct3/4 RT F

TCTTTCCACCAGGCCCCCGGCTC

Oct3/4 RT R

TGCGGGCGGACATGGGGAGATCC

Sox2 RT F

ATGATGGAGACGGAGCTGAA

Sox2 RT R

TTGCTGATCTCCGAGTTGTG

Foxa2 F

CTCTTCCGTGAGCAACATGA

Foxa2 R

GCGCCCACATAGGATGAC

Gata4 F

CTCTATCACAAGATGAACGGCATCAAC

Gata4 R

TCTGGCAGTTGGCACAGGAGAG

Olig2 F

CGCAGCGAGCACCTCAAATCTAA

Olig2 R

CCCAGGGATGATCTAAGCTCTCGAA
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Sox2 RT F

ATGCACCGCTACGACGTCAG

Sox2 RT R

AGGTGAAAGCTTTTATTTTGTTGAGAC

Trim28 RT F

GAGATGGAGAGCGAACAGTCTAC

Trim28 RT R

TGTCACAGCTCTCACAGAACAG

Gapdh RT F

CAAAATGGTGAAGGTCGGTGTGAA

Gapdh RT R

CAACAATCTCCACTTTGCCACTG

Esrrb RT F

CCTCATCAACTGGGCCAAGC

Esrrb RT R

TACACGATGCCCAAGATGAGAATCT

Cdx2 RT F

CAAGGACGTGAGCATGTATCC

Cdx2 RT R

GTAACCACCGTAGTCCGGGTA

Dnmt3a RT F

GTCACACAGAAGCATATCCAGGAG

Dnmt3a RT R

GTTGACAATGGAGAGGTCATTGC

Dnmt3b RT F

ATGGCTTCAAAGAATGATAAGCTCG

Dnmt3b RT R

TCTGCACTTTCTTTAACTTTGCTGT

Lsd1 RT F

GATGGGATTTGGCAACCTTAACAAG

Lsd1 RT R

AAACAAATTGACACTTGGGTCCC

Gapdh RT F

CAAAATGGTGAAGGTCGGTGTGAA

Gapdh RT R

CAACAATCTCCACTTTGCCACTG

Lefty1 RT F

CTACAACACAGCCATGCCAG

Lefty1 RT R

CTCCATTCCGAACACTAGCAGGT

Sall4 RT F

GTGCTCCAGTGAACTCCCC

Sall4 RT R

ACAGCATTTGTTGCAGATGTGA

Trim28 RT F

GAGATGGAGAGCGAACAGTCTAC

Trim28 RT R

TGTCACAGCTCTCACAGAACAG

For ChIP and MDqPCR:
Lefty1 F

GTAGCCAGCAGACAGGACAA

Lefty1 R

ATCCCCAATCCACATTCACT

Lefty2 F

AGGCCTAGCTTTTGCATCAC

Lefty2 R

TCTCCCAGAGTCGATCTTCC

Sall4 F

GAAATAAACATCTGGGAGAAGGA

Sall4 R

GGAAACCCCAGATTGAGAGA

Sox2 F

TGGCGAGTGGTTAAACAGAG

Sox2 R

TAGCGAGAACTAGCCAAGCA

Primer

Trim28 F

GGTCTGCAATTGAAGGAAGG

Trim28 R

TTAAACAGCAGGGGGTAAGG

Esrrb F

CGAGCTTCAGCTGGCTATTT

Esrrb R

GAGCTCCAGATCCCCTACAC

Ctrl F

ACCTAAACCTCATAAAGACACAACA

Ctrl R

TGACGTGTTCTTGGATTCAGT
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2.5 Results
2.5.1 Dnmt3a methylates a subset of PpG enhancers
Dnmt3a and 3b have been previously reported to methylate PpG promoters (229)
but their role in methylating PpG enhancers has not been fully defined. We tested the role
of Dnmt3 enzymes in the methylation of the known enhancers of six commonly studied
key PpGs; Lefty1, Lefty2, Esrrb, Sall4, Sox2, Trim 28 during ESC differentiation (180).
We differentiated WT and Dnmt3a-/- 3b-/- double knockout (DKO) cells (Figure 2.2 and
2.3A) and compared DNA methylation levels at these PpG enhancers (115). We used a
methylation-dependent restriction method (MD-qPCR) in which the restriction enzyme
MspJI cleaves methylated DNA (Figure 2.3B) (230). A single methylation event will
result in digestion by MspJI and loss of PCR amplification (198). The qPCR analysis
showed an increase in Cq value representing an increase in the DNA methylation at PpG
enhancers during differentiation of WT cells, which was completely absent in the DKOs
(Figure 2.3C). We further analyzed the DNA methylation at these PpG enhancers by
bisulfite sequencing (Bis-seq) (Table 2.1 and 2.2) which confirmed the results obtained
by MD-qPCR (Figure 2.1B and Table 2.3). These data support the function of Dnmt3
enzymes in methylating these sites de novo during differentiation. Dnmt3a and 3b have
distinct as well as redundant targets during early development (115). To determine
whether both enzymes are involved in methylation of these PpG enhancers, we used
Dnmt3a-/- and Dnmt3b-/- ESCs (3aKO, 3bKO) (Figure 2.2), and induced them to
differentiate as illustrated in Figure 2.3A. Analysis using MD-qPCR and Bis-seq showed
that DNA methylation at PpG enhancers in differentiating 3aKO cells was comparable to
that in DKO cells, whereas in differentiating 3bKO cells, DNA methylation gradually
increased to more than 50% of WT (Figure 2.1A, 2.1B). These data argue for a primary
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role of Dnmt3a in establishing DNA methylation at these PpG enhancers. The delayed
and lower methylation in 3bKO cells suggests that either the activity of Dnmt3a is not
fully operational in the absence of Dnmt3b or the propagation and/or maintenance of
DNA methylation established by Dnmt3a requires Dnmt3b activity suggesting that
combined activity of Dnmt3a and 3b is required to complete DNA methylation at these
sites (115, 231, 232).
Next we compared the changes in the expression of these PpGs in WT and Dnmt3
KO cells post induction of differentiation. Relative to gene expression changes post
induction of differentiation in WT, we observed that more PpGs showed a partial gene
repression in 3aKO and DKO cells compared to 3bKO cells (Figure 2.1C, 2.3D). The
average effect on the repression of all the PpGs post differentiation in Dnmt3aKO was
significant when compared to the WT (Figure 2.1D). This suggests a common role of
Dnmt3a in the repression of these PpG during differentiation. Both Dnmt3a and 3b KO
ESC differentiated into embryoid bodies (EBs), however we noticed they had aberrant
size and morphology (Figure 2.3E). Compared to WT and 3bKO cells, the 3aKO cells
also maintained a higher level of alkaline phosphatase expression post differentiation, a
marker of pluripotency (Figure 2.1E). However, the germ layer specific genes were
activated in both 3aKO and 3bKO cells post induction of differentiation (Figure 2.3F,
2.3G), indicating only a partial defect in their differentiation potential.
Although we cannot exclude the possibility that in the 3aKO cells, the absence of
DNA methylation at other Dnmt3a targets could affect the PpG repression, this
observation resembles the published effects of Lsd1 inhibition on PpG repression. During
ESC differentiation, Lsd1-Mi2/NuRD removes histone H3K4me1 and H3K27Ac from
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PpG enhancers and the demethylation activity of Lsd1 was shown to be critical for
complete repression of PpGs (51). Therefore, we tested the Lsd1 activity at the PpG
enhancers in DKO cells post induction of differentiation by chromatin
immunoprecipitation (ChIP) of histone H3K4me1. Comparable levels of H3K4me1 were
observed in DKO and WT cells, which were similarly reduced post induction, showing
that Lsd1 activity is unaltered at PpG enhancers in DKO cells (Figure 2.1F). These results
suggest Dnmt3a may be a potential downstream epigenetic effector of Lsd1-Mi2/NuRD
activity and could contribute to the complete repression of these PpGs. We propose that
during ESC differentiation, deacetylation and demethylation by the Lsd1-Mi2/NuRD
complex primes the histone tails to interact with the Dnmt3a-ADD domain. This
hypothesis is further supported by ChIP analysis showing an increased enrichment of
Dnmt3a at PpG enhancers in differentiated cells (Figure 2.1G).
Given that several studies have described the relationship between histone
deacetylation and DNA methylation (220), we investigated the contribution of Lsd1
activity in regulating DNA methylation by Dnmt3a at PpG enhancers during ESC
differentiation.
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Figure 2.1. Dnmt3a is the principal methyltransferase for PpG enhancer methylation.
ESC: undifferentiated embryonic stem cells and D3-D9: Days post-induction of differentiation WT: Wild
Type, 3aKO: Dnmt3a Knockout, 3bKO: Dnmt3b Knockout, DKO: Double knockout for Dnmt3a and
Dnmt3b. (A and B) DNA methylation analysis of the PpG enhancers (listed below) by MD-qPCR (A) and
by bisulfite sequencing (Bis-seq) (B). For MD-qPCR (A), genomic DNA was digested with the restriction
enzyme MspJI that cuts methylated DNA, followed by qPCR at key PpG enhancers listed below
(illustration in Figure 2.3B). An increase in the Cq represents the gain in DNA methylation. Cq is the
quantification cycle. For Bis-seq (B) bisulfite-treated gDNA was used to determine the extent of CpG
methylation at these enhancers covering 3-10 CpGs on a high throughput sequencing platform (MiSeq) and
the data was analyzed using Bismark software. The number of CpGs, reads analyzed for each enhancer, and
percent CpG methylation by site in all cell lines and treatments are given in Table 2.1, 2.2, 2.3 and
Materials and Methods. (C) Gene expression analysis of PpGs by RT-qPCR in WT and Dnmt3 KO cells;
undifferentiated and post induction of differentiation. Gene expression is normalized to Gapdh and
represented relative change to gene expression in ESC. (D) Average gene expression change across all 8
PpGs D9 post differentiation in Dnmt3aKO compared to WT. P-values are derived from paired Student’s
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paired T-test (E) Alkaline phosphatase (AP) staining for pluripotency in ESCs and differentiated cells 9
days post-induction, where the presence of dark blue stain indicates positive for AP expression and
pluripotency. (F, G) ChIP-qPCR was used to determine percent enrichment of H3K4me1 in WT and DKO
cells (F) and Dnmt3a (G) at PpG enhancers pre- and post- induction of differentiation. For A, C, F, and G
average and SD are shown for each gene.
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Figure 2.2: Dnmt3 knockout cell lines.
Single and double Dnmt3 knockout cell lines were verified by PCR. Bands indicated by arrows show the
presence of the Dnmt3 genes.
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Figure 2.3: ESC differentiation and DNA methylation analysis at PpG enhancers in WT and Dnmt3
KO cells
ESC: undifferentiated embryonic stem cells and D3-D9: Days post-induction of differentiation WT: Wild
Type, 3aKO: Dnmt3a-/- 3bKO: Dnmt3b-/-, DKO: Dnmt3a-/- Dnmt3b-/-. (A) Differentiation is induced by
withdrawal of leukocyte inhibitory factor (LIF) and by addition of retinoic acid (RA) in the medium at D3
post differentiation. (B) Scheme of MD-qPCR. Extracted genomic DNA is digested sequentially by CviQI,
then the methyl-sensitive enzyme MspJI. The specific enhancers regions are amplified by qPCR. Arrows
adjacent to DNA represent primer sites, open circles represent unmethylated CpG, and closed circles
methylated CpG. (C) DNA methylation analysis of PpG enhancers by MD-qPCR in WT and DKO cells
undifferentiated and post induction of differentiation. (D, F, G) Gene expression analysis of PpGs (D) germ
layer genes (F and G) in ESC and cells post induction of differentiation by RT-qPCR. The data are
normalized to Gapdh control and the change in Cq values is relative to that of undifferentiated cells (ESC),
which is set to 0. (E) Microscopic images from embryoid bodies 3 days post differentiation for WT and
Dnmt3 KO lines. All panels are 20X magnification. Data shown are the average and SD, details can be
found in Materials and Methods.
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2.5.2 Lsd1-mediated demethylation triggers Dnmt3a activity at PpG enhancers
In contrast to other histone demethylases, Lsd1 uniquely catalyzes an FADdependent oxidation reaction to remove H3K4me1. It is specifically inhibited by the
monoamine oxidase inhibitors pargyline (Prg) and tranylcypromine (TCP). Both of these
inhibitors have been earlier demonstrated to inhibit Lsd1 activity and PpG repression
during ESC differentiation (51, 233, 234). With the use of these inhibitors, we asked
whether Dnmt3a activity is regulated by Lsd1-mediated histone demethylation at the
examined PpG enhancers. The speculation that the Lsd1 inhibition will suppress Dnmt3a
activity is supported by fluorescence polarization and isothermal titration calorimetry
experiments, which show that H3K4me1 decreases the interaction of Dnmt3-ADD with
H3 tails by 18- and 2- fold, respectively (166, 223). Compared to H3K4me3, although
H3K4me1 partially blocked this interaction in vitro, we anticipated the possibility of a
significant effect in vivo. To test our hypothesis, ESC differentiation was induced in the
presence of Prg or TCP (Figure 2.5A). ChIP of H3K4me1 at a subset of the enhancers of
PpGs confirmed the suppression of Lsd1 activity in inhibitor-treated, induced cells
(Figure 2.4A). Consistent with earlier studies, treatment of Lsd1 inhibitors during
differentiation lead to cell death (51, 235), but the surviving cells retain pluripotency as
shown by SSEA-1 and AP staining (Figure 2.4B). We also observed weak PpG
repression and no significant change in the activation of germ layer-specific genes in
Lsd1 inhibitor-treated induced cells (Figure 2.4, 2.4D, 2.5B and 2.5C) confirming the
previously known role of Lsd1 in regulation of PpG repression during ESC
differentiation. Since the measurable increase in DNA methylation takes places 4-5d post
differentiation in untreated WT cells (Figure 2.1A and 2.1B), we determined the effect of

44
Lsd1 inhibition on the establishment of DNA methylation by analyzing these early time
points using MD-qPCR and Bis-seq. Gain of DNA methylation at these PpG enhancers
during differentiation was restricted in cells treated with Lsd1 inhibitors, suggesting a
link between Lsd1 activity and DNA methylation at these PpG enhancers (Figure 2.4E,
2.4F). Consistent with these results, ChIP analysis showed that the enrichment of Dnmt3a
at the PpG enhancers is reduced in Prg-treated induced cells (Figure 2.4G).
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Figure 2.4: Lsd1 inhibition restricts establishment of DNA methylation at PpG enhancers by
Dnmt3a.
ESC: undifferentiated embryonic stem cells, and ESC-LIF: Cells induced to differentiate. (A) ChIP-qPCR
was used to determine the percent enrichments of H3K4me1 at the PpG enhancers in ESC and cells 7 days
post- induction of differentiation (ESC-LIF) in absence and presence of Lsd1 inhibitors, Prg: Pargyline,
TCP: Tranylcypromine. (B) Alkaline phosphatase staining (blue) and SSEA-1 immunofluorescence (red) in
ESCs and cells 9 days post induction of differentiation (ESC-LIF) in absence and presence of pargyline,
where positive staining indicates pluripotency. (C) Gene expression analysis of PpGs using RT-qPCR in
ESCs and cells 9 days post induction of differentiation (ESC-LIF) in absence and presence of Lsd1
inhibitors. Gene expression is normalized to Gapdh and represented relative to gene expression in ESC. (D)
Average expression change with SEM across all loci shown in C; (E) DNA methylation analysis of the PpG
enhancers in ESCs and cells 5 days post induction of differentiation in absence and presence of pargyline
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and TCP was assayed by MD-qPCR as in Figure 2.1A. (F) Bis-seq was used to determine the extent of
CpG methylation (details same as Figure 2.1B) and the data are the average and SEM of 6 PpG enhancers
shown in E. (G) Percent enrichment of Dnmt3a using ChIP-qPCR at PpG enhancers in ESC and cells 7
days post- induction of differentiation (ESC-LIF) in absence and presence of Lsd1 inhibitors. For D and F,
P-values are derived from Student’s paired t-test using GraphPad Prism. For A, C, E, and G average and
SD are shown for each gene.
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Figure 2.5: Effect of Lsd1 inhibitors on epigenetic state and gene expression.
ESC: undifferentiated embryonic stem cells and D3-D9: Days post-induction of differentiation. D2-D8:
Days post-induction of differentiation by doxycycline. (A, D) Differentiation of ESCs is induced by
withdrawal of leukocyte inhibitory factor (LIF) and by addition of retinoic acid (RA) in the medium at D3
post-differentiation and ZHBTc4 are differentiated by LIF withdrawal and doxycycline treatment (Dox) to
knockdown Oct4. Cells are pre-treated with pargyline (Prg) or Tranylcypromine (TCP) for 6 hrs before
induction of differentiation, then differentiated in the presence of either inhibitor. (B, C, E and F) Gene
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expression analysis of germ layer genes (B, E) and PpGs (C, F)) by RT-qPCR in E14T (B, C) and ZHBTc4
cells (E, F) post induction of differentiation. The data are normalized to Gapdh control and the change in
Cq values is relative to that of undifferentiated cells (ESC) which is set to 0. Data shown are the average
and SD, as described in the Materials and Methods.
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2.5.3 Effect of the master regulator Oct4 on gain of DNA methylation at PpG
enhancers
Because Lsd1 inhibitors block differentiation of ESCs, the gain of DNA
methylation at PpG enhancers may be affected by other protective mechanisms that
include binding of the master transcriptional regulator of PpGs, Oct4 to these PpG
enhancers. Gene expression analysis of the Prg-treated and induced cells showed a higher
expression of Oct4 (Figure 2.4C). We reasoned that in these conditions, high Oct4
expression may result in its continued binding to PpG regulatory elements, thus overriding the effect of epigenetic regulators in the repression pathway. To uncouple the
effect of Oct4-reinforced transcriptional activation from Lsd1 regulation of DNA
methylation, we used the transgenic ESC line, ZHBTc4 (Z), in which doxycycline
treatment induces Oct4 repression and consequent cell differentiation into trophectoderm
(Figure 2.5D and 2.5E) (236). Similar to their effect in WT ESCs, in Z cells Lsd1
inhibitors prevented complete histone H3K4me1 demethylation (Figure 2.6A), impeded
differentiation (Figure 3B) and caused incomplete repression of PpGs (Figure 2.6C, 2.6D
and 2.5F). Further, compared to control differentiating Z cells, DNA methylation in
treated cells was significantly reduced (Figure 2.6E-2.6F) demonstrating that in the
absence of Oct4 expression, inhibition of Lsd1 activity is sufficient to impede DNA
methylation by Dnmt3a at PpG enhancers post induction of differentiation. ChIP analysis
showed that similar to E14T cells, the enrichment of Dnmt3a at the PpG enhancers is
reduced in Prg-treated induced cells (Figure 2.6G). The effect of Lsd1 inhibition on DNA
methylation was not due to reduced expression of Lsd1, Dnmt3a, 3b or Dnmt1 (Figure
2.7A-2.7B) and did not affect global DNA methylation levels as evidenced by the
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integrity of genomic methylation at the repetitive elements, which is comparable to
untreated differentiating ESCs (Figure 2.7C). Taken together, our results support a
functional interaction between the Lsd1-dependent histone H3K4 demethylation and
Dnmt3a-catalyzed DNA methylation at these examined PpG enhancers.
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Figure 2.6: Lsd1 inhibition affects DNA methylation at PpG enhancers in absence of Oct4
expression.
ESC: undifferentiated embryonic stem cells, and ESC -LIF +Dox: Cells induced to differentiate by
Doxycycline treatment. (A) Percent enrichments of H3K4me1 using ChIP-qPCR at the PpG enhancers in
ESC and cells 4 days post-induction of differentiation (ESC -LIF +Dox) normalized to a negative control
region in absence and presence of Lsd1 inhibitors, Prg: Pargyline, TCP: Tranylcypromine. (B) Alkaline
phosphatase (AP, blue stain) and SSEA-1 immunofluorescence staining (red stain) for pluripotency in
ESCs and cells 8 days post-induction of differentiation (ESC -LIF +Dox) in absence and presence of
pargyline, where positive staining indicates pluripotency. (C) Gene expression of PpGs by RT-qPCR in
ZHBTc4 cells untreated and treated with Lsd1 inhibitors for 8 days post induction of differentiation. Gene
expression is normalized to Gapdh and represented relative to gene expression in ESC. (D) Average
expression change with SEM across all loci shown in C; (E) DNA methylation analysis of the PpG

52
enhancers (listed below) in ESCs and cells 4 days post-induction of differentiation in absence and presence
of pargyline and TCP was assayed by MD-qPCR as in Figure 2.1A. (F) Bis-seq was used to determine the
extent of CpG methylation (details same as Figure 2.1B) and the data are the average and SEM of 6 PpG
enhancers shown in E. (G) Percent enrichment of Dnmt3a using ChIP-qPCR at PpG enhancers from cells
pre- and 4 days post-induction of differentiation in presence and absence of pargyline. P-values are derived
from Student’s paired t-test using GraphPad Prism. For A, C, E, and G average and SD are shown for each
gene.
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Figure 2.7: Effect of pargyline treatment on Dnmt gene expression and global DNA methylation.
ESC: undifferentiated embryonic stem cells, for WT D3-D9: Days post induction of differentiation; for
ZHBTc4, D2-D6: Days post induction of differentiation. (A) Gene expression analysis of Dnmt3a, 3b and
Lsd1 by RT-qPCR in WT and ZHBTc4 cells that are induced in the presence or absence of pargyline. The
data are normalized to Gapdh control and the change in Cq values is relative to that of undifferentiated
cells (ESC) set to 0. Data shown are the average and SD of replicates as described in Materials and
Methods. (B) Western blot for Dnmt1 expression in cells induced to differentiate in presence and absence
of Lsd1 inhibitor pargyline (Prg). 70 µg of total cell extract from differentiated cells (D7 for WT and D6
for ZHBTc4) was loaded. Gapdh acts as a control. (C) H: HpaII and M: MspI. HpaII cuts only
unmethylated DNA at CCGG sites and MspI cuts at the same site irrespective of DNA methylation. DNA
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methylation of genomic DNA from WT and ZHBTc4 cells pre- and post-induction of differentiation in
presence or absence of the Lsd1 inhibitor pargyline was analyzed by methylation dependent restriction
followed by Southern blot. Probes were used for minor satellite or Line1 repeat elements.
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2.5.4 Histone deacetylation by Mi2/NuRD and DNA methylation at PpG enhancers
Previous studies have shown that in ESCs, Lsd1 is part of the Mi2/NuRD
complex (51, 96, 98, 237). During ESC differentiation, dissociation of the OSN
coactivator complex (Oct4/Sox2/Nanog-HATp300) from the PpG enhancers triggers the
histone deacetylase activity of the Mi2/NuRD complex, which is critical for Lsd1mediated histone demethylation. Since the acetylation of histones is known to inhibit the
interaction of unmethylated histone tails with the Dnmt3a-ADD domain (167, 225), we
asked if Dnmt3a activity at PpG enhancers was blocked by the disruption of the histone
deacetylase activity of the Mi2/NuRD complex in Lsd1 inhibitor treated cells. We first
verified histone deacetylation during differentiation at a subset of PpG enhancers by ChIP
of histone H3K27Ac. Surprisingly, deacetylation was partially inhibited in Prg-treated
cells (Figure 2.8A ) (48, 238), which may be a consequence of the recursive nature of
epigenetic processes (239-243). Therefore, to distinguish the potential effect of remnant
histone acetylation from that of histone methylation on Dnmt3a activity in Prg-treated
cells, we induced differentiation of ESCs in the presence of the p300 HAT inhibitor
C646, in addition to the treatment with Prg (Figure 2.9A) (244). Treatment of cells with
C646 did not affect the differentiation, however treatment with pargyline together with
C646 impeded differentiation as shown by AP and SSEA-1 staining (Figure 2.8B). The
decrease of histone acetylation at PpG enhancers in C646-treated differentiated cells
(Figure 2.8A) is expected to be permissive for Lsd1 activity and DNA methylation by
Dnmt3a. Consistent with this, we observed a decrease in H3K4 methylation and an
increase in DNA methylation in C646 treated cells (Figure 2.8C, 2.8D and 2.8E).
Simultaneous treatment with Prg and C646 can therefore be used to determine the direct
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impact of histone demethylation on Dnmt3a activity (Figure 2.8C). When ESCs were
induced to differentiate in the presence of both C646 and Prg, gain of DNA methylation
at these PpG enhancers was strongly inhibited (Figure 2.8D and 2.8E), even though the
histone acetylation was similarly reduced in C646 treated cells with and without Prg
(Figure 2.8A).
A similar effect on the gain of DNA methylation at the PpG enhancers was seen
in Z cells when they were induced to differentiate by doxycycline treatment in the
presence of Prg and/or C646 (Figure 2.8F). Use of Z cells in these experiments
uncouples the protective effects of both Oct4 and histone acetylation from the regulatory
role of Lsd1-mediated histone demethylation on Dnmt3a-catalyzed DNA methylation at
PpG enhancers. Although Dnmt3a could have other targets during differentiation, its
coordinated activity with Lsd1 is likely to be specific to PpG enhancers, since the Lsd1
activity was shown to be largely recruited at the PpG enhancers during ESC
differentiation (51). Taken together, these data establish a dominant effect of Lsd1
inhibition on the mechanism that regulates the establishment of DNA methylation at a
subset of PpG enhancers during ESC differentiation and suggest a functional link
between Lsd1 activity and DNA methylation by Dnmt3a.
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Figure 2.8: Effect of histone deacetylation on DNA methylation at PpG enhancers.
ESC: undifferentiated embryonic stem cells, and ESC -LIF: E14T cells induced to differentiate, ESC LIF+Dox: ZHBTc4 cells induced to differentiate. (A) ChIP-qPCR was used to determine the percent
enrichments of H3K27ac at the PpG enhancers in ESC and cells 7 days post-induction of differentiation
(ESC-LIF) in absence and presence of pargyline and/or C646, Prg: Pargyline, C646: p300 Histone
acetyltransferase inhibitor. (B) Alkaline phosphatase staining (blue) and SSEA-1 immunofluorescence
(red) in ESCs and cells 9 days post induction of differentiation (ESC-LIF) in absence and presence of C646
and C646 with pargyline, where positive staining indicates pluripotency. (C) ChIP-qPCR was used to
determine the percent enrichments of H3K4me1 at the PpG enhancers in ESC and cells 7 days postinduction of differentiation (ESC-LIF) in absence and presence of pargyline and/or C646. (D) DNA
methylation analysis of the PpG enhancers in ESCs and cells post induction of differentiation in absence
and presence of pargyline and/or C646 was assayed by MD-qPCR as in Figure 2.1A. (E and F) Bis-seq was
used to determine the extent of CpG methylation at these enhancers in E14T cells (E) or ZHBTc4 cells (F)
and the data was analyzed using Bismark software (details same as Figure 2.1B) and the data are the
average and SEM of 6 PpG enhancers shown in D. P-values are derived from Student’s paired t-test. For A,
C, and D average and SD are shown for each gene.
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Figure 2.9: Effect of C646 and pargyline treatment on DNA methylation during ESC differentiation
and effect of Myc-tagged Dnmt3a ADD expression on DNA methylation.
ESC: undifferentiated embryonic stem cells, D3-D9: Days post-induction of differentiation and D4: Days
post-induction of differentiation by doxycycline. (A) Cells were differentiated as in Figure 2.5, additionally
cells were treated with C646 24 hours before the induction of differentiation and the treatment was
continued throughout differentiation. Prg: pargyline, C646: p300 Histone acetyltransferase inhibitor. (B)
Long exposure of ChIP-Western with ESC-LIF samples were probed for Lsd1 after co-IP with the
indicated antibodies. A non-specific band in the IgG control migrates at a higher weight than expected for
Lsd1. (C) Western blot showing expression of Myc-Dnmt3a ADD using anti-Myc antibody. -actin serves
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as a loading control. 50 µg of whole cell extract from transgenic ESC carrying Myc-ADD expression
vector or empty vector was loaded per well, and blotted using anti-Myc and anti-Actin antibodies. (D)
Alkaline phosphatase staining (blue) and SSEA-1 immunofluorescence (red) in ESCs, where positive
staining indicates pluripotency. (E) H: HpaII and M: MspI. HpaII cuts only unmethylated DNA at CCGG
sites and MspI cuts at the same site irrespective of DNA methylation. DNA methylation of genomic DNA
from undifferentiated cells from the indicated cell lines was analyzed by methylation dependent restriction
followed by Southern blot. Probes were used for minor satellite or Line1 repeat elements.
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2.5.5 Interaction of Dnmt3a with Lsd1-Mi2/NuRD complex
Previous studies have shown that Lsd1 and Mi2/NuRD form a complex in
undifferentiated ESCs and associate with PpG enhancers while they are in the active
state. The enzymatic activity of the Lsd1-Mi2/NuRD complex is however only triggered
upon dissociation of the OSN complex during ESC differentiation (51, 98). Therefore,
we tested the interaction of Dnmt3a with the Lsd1-Mi2/NuRD complex both in the
undifferentiated ESCs and in differentiated cells. Reciprocal co-immunoprecipitation
(Co-IP) from ESC nuclear extracts and from cross-linked chromatin using Lsd1 or
Dnmt3a antibodies revealed the presence of Dnmt3a along with known components of
the Lsd1- Mi2/NuRD complex (Figure 2.10A and 2.10B). Similar Co-IP experiments to
determine the presence of Dnmt3b in Lsd1-Mi2/NuRD complex showed no specific
interaction, which may also be due to low specificity of the available antibodies.
Compared to that in undifferentiated ESCs, a weaker or no interaction of Dnmt3a with
the Lsd1 complex was observed in crosslinked chromatin from differentiated cells
(Figure 2.9B). This suggests that post differentiation, Lsd1-Mi2/NuRD activity allows the
subsequent interaction of Dnmt3a-ADD with histone tails, after which the interaction of
Dnmt3a with the Lsd1-Mi2/NuRD complex may not persist and may not be required.
Lsd1-facilitated interaction of Dnmt3a with histone tails is supported by the results from
Dnmt3a ChIP (Figure 2.1G) that showed a higher enrichment of Dnmt3a at these PpG
enhancers post differentiation, which is reduced by Lsd1 inhibitor treatment (Figure
2.4G, 2.6G). This higher enrichment of Dnmt3a post differentiation is because its
interaction with demethylated histone tails could facilitate its crosslinking to chromatin.
Together, these data suggest a model in which the active enhancers of PpGs are poised
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for repression by the presence of a proximally located repressive Lsd1Mi2/NuRD/Dnmt3a complex, which is activated as cells begin to differentiate (Figure
2.11C).
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Figure 2.10: Dnmt3a is associated with the Lsd1-Mi2/NuRD complex.
ESC: undifferentiated embryonic stem cells, ESC -LIF: Days post induction of differentiation, 3aKO:
Dnmt3a knockout. (A) Nuclear extract was prepared from WT and 3aKO ESCs and used in co-IP (coimmunoprecipitation) performed with anti-Dnmt3a or anti-Lsd1 antibody and blotted to probe for Lsd1Mi2/NuRD subunits (Lsd1, Hdac1, and Chd4) and Dnmt3a. Input (5%) was loaded as a control. (B) Crosslinked chromatin from ESC and cells 7 days post differentiation was used for a ChIP-Western performed
with anti-Dnmt3a or anti-Lsd1 and blotted to probe for Lsd1 and Dnmt3a. Input (20%) was loaded as a
control.
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2.5.6 ADD domain-histone interaction guides PpG enhancer DNA methylation
Our data suggest that during ESC differentiation Lsd1-Mi2/NuRD activity at a
subset of PpG enhancers induces a local interaction between histone H3K4me0 and the
Dnmt3a-ADD domain, thus facilitating de novo DNA methylation at these sites. To
investigate the role of the interaction of the Dnmt3-ADD domain with H3K4me0 histone
tails in PpG enhancer DNA methylation, we created transgenic ESCs overexpressing the
Myc-epitope tagged-ADD domain of Dnmt3a Figure 2.9C). We confirmed the
pluripotency of these lines by SSEA and AP staining (Figure 2.9D) and induced them to
differentiate. We reasoned that overexpression of this domain can potentially compete
with endogenous Dnmt3a to interact with the demethylated histone tails at the examined
PpG enhancers, thereby affecting enhancer DNA methylation during differentiation.
ChIP analysis showed the binding of the recombinant Myc-ADD domain at these PpG
enhancers post differentiation (Figure 2.11A). Indeed, accumulation of DNA methylation
at these PpG enhancers in the Myc-ADD expressing cells was significantly reduced both
at 5d and 9d post differentiation compared to the control cells (Figure 2.11B). We noticed
a more substantial difference in DNA methylation at 5d post induction that narrowed as
differentiation proceeded. This is because the Myc-ADD competes with the binding and
not the activity of endogenous Dnmt3a; therefore, the DNA methylation deposited for
every Dnmt3a binding event could be further propagated by an Lsd1 independent
mechanism of Dnmt1 or by Dnmt3b. A partial gain in DNA methylation at these PpG
enhancers in 3bKO cells supports this premise (Figure 2.1A, 2.1B). We further examined
the potential effect of Myc-ADD on global DNA methylation which showed no change in
DNA methylation at Line1 elements and minor satellite repeats (Figure 2.9E). A
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significant inhibition of PpG enhancer DNA methylation by Myc-ADD is consistent with
the model that the interaction of the Dnmt3a-ADD domain with demethylated histone
tails at PpG enhancers regulates the establishment of de novo DNA methylation during
the early phase of differentiation.
Taken together our data suggest that the histone editing activity of the Lsd1Mi2/NuRD complex at a subset of PpG enhancers functions as an epigenetic switch to
locally activate Dnmt3a, leading to site specific DNA methylation and enhancer
repression (Figure 2.11C).
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Figure 2.11: DNA methylation at PpG enhancers is facilitated by histone H3 and Dnmt3a-ADD
interaction.
ESC: undifferentiated embryonic stem cells, ESC-LIF: Cells induced to differentiate, D5, D9: Days postinduction of differentiation, V: empty Myc vector control, and ADD: Myc-3a ADD expressing cells. (A)
ChIP-qPCR was used to determine the percent enrichments of Myc-Dnmt3a ADD at the PpG enhancers in
transgenic ESC lines expressing Myc empty vector or Myc Dnmt3a-ADD domain and in cells 9 days postinduction of differentiation (ESC-LIF); the percent enrichment is normalized so that the enrichment of cells
with the empty vector is subtracted from the enrichment of ADD expressing cells. Average and SD is
shown for each gene. (B) DNA methylation at PpG enhancers as shown in A in transgenic ESC lines
expressing Myc empty vector or Myc Dnmt3a-ADD domain 5 days post induction of differentiation was
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assayed by Bis-seq (details same as Figure 2.1B). The percent methylation in D5 and D9 samples were
normalized to ESC. P-values are derived from Student’s paired t-test. (C) Model illustrating the epigenetic
switch at PpG enhancers that activates Dnmt3a through histone-ADD interaction. At the active PpGs, the
enhancer is bound by the OSN coactivator complex and the chromatin is acetylated and methylated. Upon
differentiation, dissociation of the coactivator complex triggers the activity of the Lsd1-Mi2/NuRD
complex, which removes H3K27Ac and H3K4me1 at PpG enhancers. This in turn activates Dnmt3a
through the interaction of its ADD domain with the newly generated H3K4me0 histone tails permitting
site-specific DNA methylation. Ac: Acetylation; *: histone methylation; closed circle: DNA methylation.
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2.6 Discussion
Current investigations have advanced our understanding of the contribution of
epigenetic mechanisms in the regulation of pluripotency and cellular differentiation in
normal and diseased states. However, the mechanisms that regulate the interplay between
the readers and writers of epigenetic marks and their subsequent impact on gene
expression have not been fully elucidated. In this study, we identified a functional role for
Dnmt3a as a reader and effector in a queue of epigenetic events, where local histone
deacetylation and demethylation by Lsd1-Mi2/NuRD complex allows the interaction and
specific activation of Dnmt3a at a subset of PpG enhancers.
Earlier investigations on the regulation of DNA methylation at PpG regulatory
elements have shown that both Dnmt3a and 3b are required for de novo methylation of
the promoters of Oct4 and Nanog (229) and the interaction between G9a histone
methyltransferase and Dnmt3a is required for DNA methylation at the Oct4 promoter
(156, 157, 245, 246). Other studies have shown that G9a may not be required for DNA
methylation at the Oct4 enhancer (224, 247). Our experiments using ESCs with targeted
deletions of Dnmt3a and 3b (115) together with ChIP experiments first identify Dnmt3a
as the primary MTase required for methylation of a subset of PpG enhancers. A
supporting role of Dnmt3b in this process is suggested by delayed and partial gain of
DNA methylation post differentiation in Dnmt3bKO ESCs. Further, our data suggests
that DNA methylation at these PpG enhancers may contribute to the stable repression of
PpGs during differentiation. Compared to WT cells, repression of some PpGs in
Dnmt3aKO cells was partially affected suggesting that Dnmt3a-mediated DNA
methylation is one of several processes that together promote complete repression of
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PpGs (Figure 2.1C). Additionally, in Dnmt3aKO cells, there was little or no effect on the
activation of lineage specific genes during differentiation (Figure 2.3F). Since a
combination of PpG repression and lineage-specific gene activation is required to drive
differentiation, these deficiencies may be insufficient to block development in utero thus
explaining the ability of the Dnmt3a KO mice to reach term although they are born
runted and die in less than 4 weeks after birth (115). Consistent with this argument we
observed that 3aKO ESCs make embryoid bodies, albeit small (Figure 2.3E), indicating
that they can differentiate even though the PpG are not fully repressed.
Our data suggests that the activity of Dnmt3a at these PpG enhancers is regulated
by the upstream Lsd1-Mi2/NuRD activity, which facilitates the binding of Dnmt3a-ADD
domain to histone tails post differentiation. The inhibitory effect of the recombinant MycADD domain on DNA methylation of these PpG enhancers confirms the mechanistic role
of the interaction between the Dnmt3a-ADD domain and demethylated histone tails
(H3K4me0) in regional specificity of Dnmt3a activity. Previous studies showing that
Lsd1-Mi2/NuRD activity is localized at the PpG enhancers (51) suggest that this
mechanism might specifically regulate the DNA methylation at these sites facilitated by
the interaction of Dnmt3a with the Lsd1-Mi2/NuRD complex. Although the histone
modification H3K4me0 is widely distributed in the mammalian genome, DNA
methylation of these sites in ESCs and differentiated cells is largely maintained through
mechanisms that are independent of Lsd1 activity and presence of the histone H3K4me0
modification (248-250) which is supported by our data showing no change in DNA
methylation at the repetitive elements in Lsd1 inhibitor treated cells.
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Previous studies have shown that continuous passage of Lsd1 KO ESCs leads to a
progressive loss of DNA methylation at repetitive elements genome-wide due to loss of
Dnmt1 protein (235). Under our experimental conditions, Lsd1 inhibition during
induction of differentiation had no effect on Dnmt1 protein levels (Figure 2.7B) or on
global DNA methylation (Figure 2.7C). In our studies, we exposed ESCs to Lsd1
inhibitors only 6 hrs prior to induction of differentiation and induced them for 8-9d in the
presence of these inhibitors. Therefore, most of the inhibitor treatment was post induction
of differentiation in contrast to earlier studies where Lsd1 KO ESC were maintained and
passaged in the pluripotent state, leading to reduced stability of Dnmt1 protein. This
argues for the potential influence of the ESC state on the mechanism regulating Dnmt1
stability. Further, the near absence of DNA methylation in differentiated 3aKO cells
suggests that the presence of Dnmt1 cannot compensate for the absence of Dnmt3a in
establishing methylation at the PpG enhancers (Figure 2.1A and 2.1B). Taken together,
our data suggest that inhibition of DNA methylation at PpG enhancers in Lsd1 inhibitortreated cells is likely due to its effect on Dnmt3a activity rather than the loss of Dnmt1.
In this study we also addressed the potential impact of the known protective
mechanisms, which include the transcription factor Oct4 and histone acetylation, on gain
of DNA methylation at these PpG enhancers in Lsd1 inhibitor treated cells. Use of Z cells
allowed us to control the potential counteracting effects of the coactivator Oct4. Similar
to E14T cells, although Lsd1 inhibition significantly impeded the gain of DNA
methylation in Z cells, comparing Figure 2.4 to Figure 2.6, we indeed noticed that the
effect on DNA methylation is less robust in Z cells. Use of C646 (a HAT inhibitor) and
Prg during differentiation uncoupled the effect of histone acetylation and histone
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methylation on deposition of DNA methylation. We conclude that under these
experimental conditions, deacetylation of histones is not sufficient to recruit Dnmt3a
activity in the presence of H3K4me1 at PpG enhancers. However, this does not exclude
the inhibitory effect of histone acetylation on the interaction of the Dnmt3a-ADD with
histone tails when these enhancers are in the active state. We anticipate that in the ESC
state, when PpG enhancers are active, histone acetylation together with histone
methylation block the interaction of the Dnmt3a-ADD domain with histone H3 tails.
Recent structural studies have shown that the ADD domain of Dnmt3a autoinhibits its
catalytic activity by sterically blocking its DNA binding domain and the interaction of the
ADD domain with unmethylated histone tails relieves this autoinhibition (168). Our CoIP and ChIP-western experiments show that Dnmt3a associates with the Lsd1-Mi2/NuRD
complex in undifferentiated ESCs. Based on these data, we speculate that in ESCs
Dnmt3a associates with the Lsd1-Mi2/NuRD complex in its auto-inhibited state, poised
to be activated during ESC differentiation. As differentiation proceeds, the Lsd1Mi2/NuRD complex deacetylates H3K27 and demethylates H3K4 residues and the
resulting “edited” histone H3 tails interact with Dnmt3a-ADD domain and locally
activate the enzyme.
These observations may also have potential implications for regulation of DNA
methylation of other genomic elements with varying degrees of histone H3K4
methylation and histone acetylation, thus instructively creating tissue specific patterns of
DNA methylation during differentiation. Therefore, it would be interesting to see if this
represents a common mechanism for enhancer-mediated regulation of other genes
controlling cell identity. For example, both Dnmt3a and Lsd1 are known to regulate
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hematopoietic stem cell (HSC) differentiation. Lsd1 mediated repression of the
regulatory elements of hematopoietic stem and progenitor cell (HSPC) genes is required
to fully silence these genes for proper hematopoietic maturation (251), and loss of
Dnmt3a in HSCs results in the retention of multipotency gene expression during
differentiation (252). It is possible that a similar epigenetic crosstalk mechanism may
regulate enhancer repression and stable silencing of multipotency genes, thus maintaining
the fidelity of differentiation during hematopoiesis. Additionally, several recent studies
have enumerated the role of enhancer-mediated regulation of oncogenes in various
cancers (253). Thus, our studies may have implications for the mechanisms that
contribute to aberrant gene expression in various human diseases.
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*CHAPTER 3: A REFINED DNA METHYLATION DETECTION
METHOD USING MSPJI COUPLED QUANTITATIVE PCR

*Formatted for dissertation from the article published in Analytical Biochemistry:
Petell, CJ, Loiseau , G, Gandy, R, Pradhan, S, Gowher, H. (2017) A refined DNA
methylation detection method using MspJI coupled quantitative PCR. Analytical
Biochemistry 533: 1-9.
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3.2 Abstract
DNA methylation is a highly conserved epigenetic modification with critical roles
ranging from protection against phage infection in bacteria to the regulation of gene
expression in mammals. DNA methylation at specific sequences can be measured by
using methylation dependent or sensitive restriction enzymes coupled to semi- or
quantitative PCR (MD-qPCR). This study reports a refined MD-qPCR method for
detecting gain or loss of DNA methylation at specific sites through the specific use of
MspJI or HpaII, respectively. By employing varying concentrations of DNA with
methylation ranging from 0-100%, our data provide evidence that compared to HpaII,
MspJI increases the sensitivity and accuracy of detecting relative DNA methylation gains
by MD-qPCR. We also show that the MspJI-coupled MD-qPCR can accurately determine
the percent gain in DNA methylation at the Sall4 enhancer and is more sensitive than
HpaII in detecting relative gains in DNA methylation at the Oct4 proximal enhancer
during embryonic stem cell (ESC) differentiation. The high specificity and sensitivity of
this targeted approach increases its potential as a diagnostic tool to detect relatively
smaller gains in DNA methylation at specific sites from limited amounts of sample.

3.3 Introduction
DNA methylation takes place at the N4 and C5 position of cytosine and N6 of
adenine in a sequence specific manner. In bacteria, DNA methylation is catalyzed by
methyltransferases in the restriction-modification (R-M) system that usually recognize
sequences equal to or longer than four base pairs. In mammals, DNA methylation occurs
largely at the CpG dinucleotide and is maintained post replication (113, 254). DNA
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methylation has diverse biological functions ranging from serving as a defense
mechanism in bacteria to the regulation of gene expression and repression of transposable
elements in higher eukaryotes (255). In multicellular organisms, the maintenance of DNA
methylation patterns, particularly at the regulatory elements of cell-type specific genes, is
critical for cell identity and homeostasis (256, 257). This is substantiated by evidence that
aberrant DNA methylation causes repression of tumor suppressor genes, activation of
oncogenes, and genome instability in cancer (110, 258, 259). The mechanism/s by which
DNA methylation effects gene expression are not completely understood; however, in
many cases the presence of methylated cytosine at binding sequences of transcription
factors in the regulatory elements of genes can preclude their binding and affect gene
regulation (208, 260). Therefore, an accurate determination of the changes in DNA
methylation at specific loci between normal and diseased states has the potential to be
used as a biomarker.
Considerable effort has led to the development of various methods with improved
speed and accuracy for measuring DNA methylation in its sequence context. The gold
standard method for DNA methylation measurement is sodium bisulfite conversion. In
this method, sodium bisulfite reacts with unmethylated cytosines, and converts them to
uracil, whereas the methylated cytosines are not affected (184, 190). Combined with
whole genome sequencing, bisulfite conversion provides a high-resolution map of the
DNA methylation at a single cytosine level for the entire genome. Methylation-dependent
restriction (MDR) employs the R-M systems of bacteria to detect DNA methylation. In
this method, the methylation-sensitive restriction enzyme, such as HpaII or HhaI, cleaves
the unmethylated DNA that is detected as a change in the DNA length by Southern Blot
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or PCR (185-189, 191, 261, 262). Hybrid methods, such as Combined Bisulfite
Restriction Analysis (COBRA) are used to detect methylation by scoring for the loss of
restriction enzyme sites such as TaqI and BstUI after bisulfite conversion of DNA (192).
These hybrid techniques allow for the quantification of lower amounts of DNA
methylation at a specific site of the genome, but are tedious and require long sample
preparation time.
Gain or loss of DNA methylation at specific genomic sites can be examined by
bisulfite conversion or more conveniently by MD-PCR. Due to its easy sample
preparation, MD-PCR affords a simple and readily accessible means of determining the
changes in DNA methylation at specific sites across multiple samples (193, 194). This
can be particularly improved when combined with quantitative-PCR (195, 197, 263-265).
The most popular enzymes used in MD-PCR, such as HhaI and HpaII, are blocked by
DNA methylation at their recognition sites. Therefore, use of these enzymes to quantify
gain of methylation by PCR amplification is potentially limited by the degree of
methylation. This is because a small increase in methylation may result in a minor
increase in the template concentration, which may not be enough to cause a detectable
change in the PCR reaction. The McrBC and Mrr-like family of restriction enzymes that
in contrast specifically cleave at sequences containing a methylated cytosine can
potentially circumvent this issue (198, 199). To test this experimentally, we performed a
comparative study with HpaII and MspJI enzymes as tools to detect gain of DNA
methylation at specific sites. MspJI is a member of the Mrr-like family of restriction
enzymes.
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Our data show that compared to HpaII, using MspJI to measure DNA methylation
increases the detection limit of MD-qPCR by more than a factor of four. This difference
between HpaII and MspJI was more prominent at limiting template concentrations.
Bisulfite sequencing showed that a unique CpG site in the Sall4 enhancer gained up to
75% DNA methylation during ESC differentiation. This gain in DNA methylation at the
Sall4 enhancer was accurately measured by MD-qPCR with MspJI when compared to a
known standard. We further show that as the result of its specificity, MspJI is better
suited to detect DNA methylation at Oct4 proximal enhancer compared to the HpaII
during ESC differentiation. Together, our data support the use of MspJI in MD-qPCR as
the enzyme of choice for quantification of small increases in DNA methylation at specific
sites in the genome. This is particularly useful for detection of DNA methylation at CpG
sites that are present in regions with lower CpG content, such as enhancers and tissue
specific promoters and may influence the binding of specific transcription factors in the
vicinity resulting in the gain or loss of gene expression.
3.4 Materials and Methods
3.4.1 DNA methylation and restriction of substrates
A 100 bp region of the Sall4 enhancer containing one HpaII recognition site (5’CCGG-3’) was amplified by PCR from mouse genomic DNA and used as a substrate for
all the assays. Methylation of the substrate DNA was carried out by M. HpaII (1 U
enzyme per ug DNA) using 100 µM AdoMet (S-Adenosylmethionine) overnight. The
DNA methylation of the fragment was tested by treating it with HpaII or MspJI
restriction enzymes overnight and visualizing the cleaved product on 9% TBE-PAGE
(Figure 3.3A). The expected fragmentation pattern is illustrated in Figure 3.1. The near
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absence of cleaved fragments in the HpaII reaction and loss of the intact DNA substrate
in the MspJI reaction ensured the DNA methylation of the substrate. The unmethylated
control DNA was incubated in buffer without enzyme and treated similarly for
downstream processing. The substrates were purified using a PCR purification kit
(Qiagen). The 100% methylated or unmethylated (0% methylated) substrates were mixed
together to generate a constant concentration of methylated DNA ranging from 0% to
100% methylation. The mixtures were split equally, and restriction digests were carried
out for 2 hours or overnight at 37°C using 100 nM substrate and 1 U enzyme (HpaII,
MspJI and a no enzyme control) in 1x CutSmart buffer supplied by the manufacturer
(NEB). Care was taken to ensure that the enzyme:DNA ratio was within the published
range of activity for MspJI and well below the concentration at which off-target activity
can occur (266). The use of purified DNA substrates facilitated an accurate quantification
and therefore an appropriate use of the enzymes in these reactions. For MspJI, use of the
supplied activator was necessary to make sure that the reaction proceeded to completion.
Restriction digestion for 2 hours with MspJI may result in partial cleavage, yielding a
double stranded break on only one side of the CpG site, which does not interfere with the
detection of methylation by qPCR using primers that flank the CpG site.
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Figure 3.1: Restriction map of the Sall4 amplicon by either MspJI or HpaII.
Restriction sites for MspJI (top) and HpaII (bottom) in the 105 bp substrate used for in vitro MD-qPCR
analysis are indicated by lines vertical to the DNA. For MspJI, the cleavage site is 12 or 16 bp on the 3’ end
of the recognition site containing the methylated cytosine and each methylated cytosine on two strands of
the DNA are recognized separately. Sizes of predicted fragments are indicated. For MspJI, complete
restriction results in 32, 36 and 46 bp fragments. For HpaII, complete restriction yields 49 and 58 bp
fragments.
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3.4.2 MD-qPCR for genomic targets
Genomic DNA from undifferentiated ESCs and from cells 3-9 days post
differentiation purified using a standard phenol:chloroform isolation was digested (10 µg)
overnight at 25°C with 40 U of CviQI restriction enzyme (NEB, R0639L), which cuts
outside the region of interest. After phenol:chloroform extraction, these samples were
subjected to a second round of cleavage by MspJI (20 U) overnight at 37°C in the
presence of the supplied activator. Purified DNA was quantified by PicoGreen according
to the manufacturer’s protocol (Life Technologies, P11495) using the NanoDrop 3300
fluorospectrometer (Thermo Scientific). The primers used are listed in Table 3.1.
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Table 3.1: Primers used in this study.
List of all primers used in the study. The primers used for the one site MD-qPCR were used for both the in
vitro and in vivo qPCR reactions. The barcoding primer sequences (Adaptor and Index) are color-coded as
in Figure 3.7.
Name

Primer

Sall4 Amplicon

AGTCTCTACCTGGAGAGTCCACCTGGGGTCAGCCATGGTT
ACTCTTCCGGGAGCAGCAGCACTTGAGGGCCCTGATGTCC
TGGGAGCTGCCTTATGCCCTAACAT

Amplicon F

AGTCTCTACCTGGAGAGTCCAC

Amplicon R

ATGTTAGGGCATAAGGCAGCTC

Amplicon MD-qPCR F

TCTACCTGGAGAGTCCACCTG

Amplicon MD-qPCR R

ATGTTAGGGCATAAGGCAGCTC

Oct4 MD-qPCR F

CTTAGTGTCTTTCCGCCAGC

Oct4 MD-qPCR R

TACCCTGCTTCCCTTCCTCC

Sall4 MD-qPCR F

TCTACCTGGAGAGTCCACCTG

Sall4 MD-qPCR R

ATGTTAGGGCATAAGGCAGCTC

Sall4 Bisulfite Inner F

TATATAGAGAGGTTTAAATAAAGGGTTTTT

Sall4 Bisulfite Inner R

TTTAAAACCACTAAACATATTAAAACATAA

Sall4 Bisulfite Outer F

AGGGATTATAATTTTTTGAGTTTTAGTTTATA

Sall4 Bisulfite Outer R

AAAACCTCTAAAAAAACAATCAATACTCTTAA

Oct4 Bisulfite Inner F

TAATGGGATTTTTAGATTGGGTTTAGAAAA

Oct4 Bisulfite Inner R

TAACCCTAAACAAATACTCAACCCTTAAAT

Oct4 Bisulfite Outer F

TTTGAGGGTTATTTTTTTGTAAAGATAA

Oct4 Bisulfite Outer R

AAAAAAAATATCTAACTTCAAATTCAAA

Sall4 Bisulfite Adaptor F

ACACTCTTTCCCTACACGACGCTCTTCCGATCTTATATAGA
GAGGTTTAAATAAAGGGTTTTT

Sall4 Bisulfite Adaptor R

GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTTTAAA
ACCACTAAACATATTAAAACATAA

Sall4 Bisulfite ESC Index F

AATGATACGGCGACCACCGAGATCTACACTGAACCTTACA
CTCTTTCCCTACACGAC

Sall4 Bisulfite D5 Index F

AATGATACGGCGACCACCGAGATCTACACTGCTAAGTACA
CTCTTTCCCTACACGAC

Sall4 Bisulfite D9 Index F

AATGATACGGCGACCACCGAGATCTACACTGTTCTCTACA
CTCTTTCCCTACACGAC

Sall4 Bisulfite Index R

CAAGCAGAAGACGGCATACGAGATATCACGACGTGACTG
GAGTTCAGACGTG
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3.4.3 Quantitative PCR
Equal amounts of cleaved and uncleaved control DNA were amplified by qPCR,
using the qPCR master mix EvaGreen according to the manufacturer’s conditions
(MidSci, BEQPCR-S). 20-22 bp primers were synthesized by IDT (Integrated DNA
Technologies) using standard desalting, which allows 95-98% purity for short
oligonucleotides. Briefly, in a 15 µl reaction volume, 100 nM primers were mixed with
template (variable concentration) and 1X EvaGreen master mix. The qPCR cycling
program was: 1. 95°C, 10 min; 40 cycles of 95°C, 15 sec and 60°C, 1 min. The measured
Cq value is defined as the quantification cycle based on the MIQE guidelines and is
calculated by the Biorad CFX Manager 3.1 (226). A change in DNA methylation is
represented by normalized change in the Cq values as follows:
Equation 1: ∆𝐶𝑞 (𝑆𝑎𝑚𝑝𝑙𝑒 𝑋) = 𝐶𝑞 (𝑆𝑎𝑚𝑝𝑙𝑒𝑋)𝐻𝑝𝑎𝐼𝐼 𝑜𝑟 𝑀𝑠𝑝𝐽𝐼 − 𝐶𝑞 (𝑆𝑎𝑚𝑝𝑙𝑒 𝑋)𝐶𝑜𝑛𝑡𝑟𝑜𝑙
Equation 2a: ∆∆𝐶𝑞 (𝑀𝑠𝑝𝐽𝐼) = ∆𝐶𝑞 (𝑆𝑎𝑚𝑝𝑙𝑒 𝑋) 𝑀𝑠𝑝𝐽𝐼 − ∆𝐶𝑞 (0% 𝑀𝑒𝑡ℎ𝑦𝑙𝑎𝑡𝑖𝑜𝑛)𝑀𝑠𝑝𝐽𝐼
Equation 2b: ∆∆𝐶𝑞 (𝐻𝑝𝑎𝐼𝐼) = ∆𝐶𝑞 (𝑆𝑎𝑚𝑝𝑙𝑒 𝑋) 𝐻𝑝𝑎𝐼𝐼 − ∆𝐶𝑞 (100% 𝑀𝑒𝑡ℎ𝑦𝑙𝑎𝑡𝑖𝑜𝑛)𝐻𝑝𝑎𝐼𝐼
Equation 3: 𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝐶𝑞 (𝑆𝑎𝑚𝑝𝑙𝑒 𝑋) = 𝐶𝑞 (𝑆𝑎𝑚𝑝𝑙𝑒𝑋)𝐻𝑝𝑎𝐼𝐼 𝑜𝑟 𝑀𝑠𝑝𝐽𝐼 −
[𝑃𝑒𝑎𝑘 𝐶𝑞 − 𝐶𝑞 (𝑆𝑎𝑚𝑝𝑙𝑒 𝑋)]𝐶𝑜𝑛𝑡𝑟𝑜𝑙
For these equations, Sample X refers to one concentration of DNA with methylation
between 0% and 100% and Control refers to the DNA treated with no enzyme or DNA
cleaved by CviQI only. Note that for Equation 2a and 2b, to determine the change in
DNA methylation using MspJI and HpaII, the data are normalized to the ΔCq of the
substrate with 0% and 100% methylation, respectively. To control for loading errors, the
Cq values (Sample X) obtained for control samples with varying DNA methylation but
same concentration were subtracted from the highest Cq (Peak Cq) value obtained in the
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range. This is done for the ease of representing the data as positive numbers. The primers
used are listed in Table 3.1.
3.4.4 Statistical analysis
For each figure, data are shown as the average and standard deviation of at least
two independent experiments; each replicate has at least four technical replicates.
Graphpad Prism 6 was used to analyze the data. The values were fit using linear
regression of a non-linear fit from which the slope and standard deviation were
determined. Statistical analysis for significance was computed by using the paired
Student’s t-test.
3.4.5 Bisulfite conversion method
At a unique CpG site in the Sall4 and Oct4 enhancer, the gain of DNA
methylation during ESC differentiation was measured using bisulfite sequencing.
Genomic DNA was purified from undifferentiated ESCs and cells 5 and 9 days post
differentiation. Bisulfite sequencing was performed using the EpiTect Fast Bisulfite
Conversion Kit (Qiagen, 59802) using 1 µg of genomic DNA. Bisulfite-converted DNA
was amplified using nested primers and Taq polymerase (NEB, M0267L). Briefly, 150
ng of converted gDNA template, 400 nM primers, 200 nM dNTPs, and 2.5 U of Taq
polymerase were mixed in a 50 µL PCR reaction. The program for the outer PCR was: 1.
94°C, 4 min; 2. 55°C, 2 min; 3. 72°C, 2 min; 4. Go to 1, 1x; 5. 94°C, 1 min; 6. 55°C, 2
min; 7. 72°C, 2 min; 8. Go to 5, 34x; 9. 72°C, 7 min; 10. 4°C hold. The setup for the
inner PCR was identical except that the template DNA consisted of 2 µL from the outer
PCR. The program for the inner PCR was: 1. 94°C, 2 min; 2. 94°C, 1 min; 3. 55°C, 2
min; 4. 72°C, 2 min; 5. Go to 2, 34x; 6. 72°C, 7 min; 7. 4°C hold (Tremblay et al., 1997).
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Products from the inner PCR were gel purified (Qiagen, 28704) and used as a template
for subsequent PCRs to generate a library for high throughput sequencing. The primers
used are listed in Table 3.1.
3.4.6 Library preparation for multiplex sequencing
Bisulfite sequencing was performed to detect DNA methylation changes between
undifferentiated and differentiated cells (ESC, D5, D9). We used multiplex highthroughput sequencing to determine these changes. After bisulfite treatment and PCR, the
target site amplicons from ESC, D5 and D9 samples were tagged by a unique identifying
index sequence at the 5’ and 3’ ends that was compatible with the Ilumina MiSeq
platform. We designed a protocol to index the samples based on the TruSeq primer
construction, where an 8 bp sequence served as the unique identifier for each sample
(Figure 3.7). After bisulfite treatment and sample amplification by inner PCR, a short
linker sequence and internal TruSeq index primer binding sites were added to the DNA
through a 5-cycle PCR. Briefly, 50 ng DNA, 400 nM primers, 200 nM dNTPs, and 2.5 U
of Taq polymerase were mixed in a 50 µL PCR reaction. PCR was carried out as follows:
1. 94°C, 2 min; 2. 94°C, 1 min; 3. 55°C, 2 min; 4. 72°C, 2 min; 5. Go to 2, 4x; 6. 72°C, 7
min; 7. 4°C hold. Using 6 µl of the first PCR reaction as template, a second round of a 5cycle PCR added an 8 bp unique identifier sequence and a TruSeq i5 (forward) or i7
(reverse) single index sequence (Figure 3.7). The unique identifier sequence was used to
discriminate and sort the sequencing data for various samples (ESC, D5, D9) for analysis.
The program for the indexing PCR was identical to that of the adaptor PCR. Indexed
amplicons for each sample were purified and pooled equally to a final concentration of 10
nM. An Illumina MiSeq 500-cycle run generated paired-end 250-base reads. The reads

84
were then mapped using Bowtie2 and analyzed by Bismark for DNA methylation. The
unique identifier was used to assign the reads to specific samples. Instances of methylated
and unmethylated CpG were quantified, and the average percent methylation for each
sample was calculated with the standard deviation. The primers used are listed in Table
3.1.
3.4.7 Cell culture and differentiation
E14Tg2A ESCs were maintained in media containing LIF and induced to
differentiate by LIF withdrawal followed by retinoic acid addition as described (224,
267).
3.5 Results
3.5.1 Detection range of MD-qPCR using MspJI and HpaII restriction enzymes
The restriction enzyme MspJI cleaves DNA asymmetrically approximately 15 bp
from the 3’ end of the recognition site, 5’-mCNNR(N)9-3’/3’-GNNY(N)13-5’, when the
cytosine in its recognition site is methylated (198, 230, 266, 268). The presence of DNA
methylation can be detected by MD-PCR or MD-qPCR using enzymes such as HpaII and
HhaI that cut DNA when their recognition sites are unmethylated. Therefore, in a mixed
population with a small proportion of methylated DNA, the larger fraction of DNA that is
unmethylated is cleaved by the restriction enzymes. This results in the depletion of the
amount of template available for amplification. The delay in amplification is caused by
the lag phase in the exponential curve of the PCR or qPCR, limiting the detection of low
percentage of methylated DNA. When coupled with amplification of the target site by
quantitative PCR, low or no methylation results in high Cq values, which may be at the
upper limit of the detection range thus decreasing the accuracy of the measurement (269,
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270). On the other hand, MspJI cleaves when cytosine in its recognition sequence is
methylated leaving unmethylated DNA intact. This overcomes the limitation posed by
the lag phase of qPCR when HpaII or HhaI are used in these assays. Therefore, when
coupled to qPCR, low or no methylation results in low Cq, thus widening the detection
range of the measurement. A comparative gain in DNA methylation would therefore be
detected as an increase in Cq value (Figure 3.2).
We compared the ability of MspJI and HpaII to detect DNA methylation using a
100 bp DNA amplified from mouse Sall4 enhancer as substrate. The PCR-derived
substrate contains one CpG site in a HpaII recognition sequence (5’-CCGG-3’) which
was methylated in vitro using M. HpaII methyltransferase. The completion of DNA
methylation was tested by resistance to cleavage by HpaII and susceptibility to MspJI
restriction enzymes (Figure 3.3A). The expected fragmentation pattern is illustrated in
Figure 3.1. For the MD-qPCR assay, methylated and unmethylated substrates were
cleaved by HpaII or MspJI restriction enzymes, or a no enzyme control (Figure 3.3B).
Next, qPCR was performed using the cleaved substrate at concentrations ranging from
100 pM to 1 fM (calculated for MW of the intact substrate). The no template control was
used to define the background Cq value (23.5 ± 0.5). For the unmethylated substrate, the
Cq values for HpaII-cleaved DNA were 2 cycles higher than for the MspJI-cleaved
substrate and no enzyme controls (Figure 3.3B, left). Conversely, for the 100%
methylated substrate, the Cq values were 2 cycles higher for MspJI-cleaved DNA than the
HpaII cleaved DNA and no enzyme controls (Figure 3.3B, right). This is consistent with
the substrate specificity of each endonuclease. We were able to detect a linear change in
Cq for template concentrations ranging from 100 pM to 10 fM, after which the Cq value
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approached that of the no template control (Figure 3.3B). Using these data, we
determined the differences in the linearity of HpaII or MspJI coupled MD-qPCR for
DNA substrates with varying amounts of DNA methylation.
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Figure 3.2: Detection of DNA methylation by MD-qPCR.
A schematic representation of MD-qPCR showing the effect of the restriction enzyme used to detect
methylation on its amplification by qPCR. A) Open and closed circles represent unmethylated and
methylated CpGs respectively on the substrate DNA and the adjacent arrows represent primer binding sites
for PCR. Whereas MspJI cleaves the methylated DNA, HpaII cleaves unmethylated DNA. B) Illustration of
the PCR amplification curves representing decreasing template concentrations. Cq, quantitation cycle;
RFU, relative fluorescence units. Cleavage by MspJI reduces the template concentration with increasing
DNA methylation and vice versa for HpaII cleavage.
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3.5.2 Detection of varying DNA methylation by HpaII and MspJI in MD-qPCR
We mixed unmethylated and methylated substrate at varying ratios, ranging from
0% to 100% methylated substrate at constant concentration. This was followed by
restriction cleavage by either HpaII or MspJI or the no enzyme control. To examine the
linearity of the qPCR for HpaII or MspJI-cleaved substrates we used a substrate
concentration of 100 fM in MD-qPCR. This concentration is at the high end of the range
of genomic DNA concentrations (1-100 fM) typically used to quantify single targets in
qPCRs (270). The changes in Cq calculated as ΔΔCq (Equation 1 and 2; see methods)
were plotted as a function of percent DNA methylation. The data for both HpaII and
MspJI fit well to linear regression (R2=0.96 and R2=0.97, respectively) suggesting that
both HpaII and MspJI can detect changes in DNA methylation by MD-qPCR when the
target DNA is at high concentrations (Figure 3.3C).
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Figure 3.3: Use of MspJI or HpaII in MD-qPCR to detect DNA methylation.
(A) Representative PAGE showing completion of DNA methylation of the substrate. Briefly, 100 nM
unmethylated and fully methylated DNA was cleaved with 1 U of HpaII or MspJI enzymes overnight as
described in the Methods section. M represents the DNA maker. The expected fragmentation pattern is
shown in Figure 3.1. (B) Methylated and unmethylated DNA cleaved with HpaII or MspJI were serially
diluted for qPCR. The Cq values were plotted against the concentration of DNA and fit to linear regression.
For both substrates, the slope is linear for DNA concentrations ranging from 10 pM to ~10 fM, after which
linearity was lost. (C) Change in Cq values were plotted as a function of percent DNA methylation of
substrate cleaved by HpaII or MspJI using 100 fM DNA for qPCR. ΔΔC q was calculated by normalizing
the Cq for cleaved DNA with those derived from the no enzyme control and to C q values for 0% and 100%
methylation for MspJI and HpaII respectively (Equation 1 and 2 in methods). Averages ± the standard
deviation are shown (n ≥ 8).
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3.5.3 Effect of HpaII and MspJI on the sensitivity of MD-qPCR
We predicted that MD-qPCR using MspJI would be more sensitive than using
HpaII in detecting lower percentage of DNA methylation under limiting DNA
concentrations. To test this, we used 0-40% methylated substrate for restriction cleavage
by MspJI and HpaII. We performed two fold serial dilutions of the cleaved substrate
ranging from 100 fM to 3 fM for MD-qPCR. The Cq values normalized to the no enzyme
control (Equation 3), were plotted vs the percent methylation for each substrate dilution
(Figure 3.4A and 3.5). The slopes of the linear regression were plotted against the
substrate concentration. The data show that for the HpaII treated substrate, the magnitude
of the slope approaches zero at a higher concentration of DNA (12 fM) compared to that
for the substrate treated with MspJI (Figure 3.4B).
Together, these data suggest that when coupled with qPCR, MspJI is better than
HpaII in detecting DNA methylation gains under limiting concentrations of DNA. This
data supports a refined method of detecting gain or loss of DNA methylation at specific
sites using MD-qPCR through an alternative use of MspJI or HpaII, respectively.
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Figure 3.4: Sensitivity of MD-qPCR assay using either MspJI or HpaII.
(A) 0-40% methylated DNA was cleaved with HpaII or MspJI and qPCR was carried out at the DNA
concentrations of 100 fM, 50 fM, 25 fM, 12 fM, and 3 fM. Normalized Cq values (Equation 3) were
plotted as a function of percent DNA methylation and fit to linear regression (Plots for 50 fM, 3 fM, and
are shown in Figure 3.5). The magnitude of the slope (m) represents the change in Cq for DNA substrates
from 0% to 40% methylation. (B) The values of the slopes (m) for all concentrations were plotted against
the DNA concentration of the substrate cleaved with HpaII or MspJI. We performed a paired Student’s ttest of the slopes compared to that of the 100 fM of the substrate; * represents a p-value less than 0.05. The
m values approach zero and show a large variability at relatively higher concentrations for the HpaII
cleaved DNA when compared to the MspJI cleaved DNA. Averages ± the standard deviation are shown (n
≥ 8).
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Figure 3.5: Sensitivity of MD-qPCR assay using either MspJI or HpaII.
0-40% methylated DNA was cleaved with HpaII and MspJI and quantified by qPCR at various
concentrations of 100 fM, 50 fM, 25 fM, 12 fM, and 3 fM of which 50 fM and 3 fM, are shown here.
Normalized Cq values (Equation 3) were plotted as a function of percent DNA methylation and fit to linear
regression. Averages ± the standard deviation are shown (n ≥ 8).
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3.5.4 Detection of the temporal gain in genomic DNA methylation by MspJI-coupled
MD-qPCR
We compared the MspJI coupled MD-qPCR to bisulfite sequencing in
measurement of the temporal gain of DNA methylation at specific genomic sites. We
examined an increase in DNA methylation at the Sall4 enhancer site, which was
previously used for our in vitro assays. Sall4 is a pluripotency gene that is expressed in
ESCs and repressed upon induction of differentiation (176). This is accompanied by the
gain of DNA methylation at its enhancer element (267). We therefore used the Sall4
enhancer as a model site to measure DNA methylation of in vivo targets. To accomplish
this, ESCs were induced to differentiate by LIF withdrawal and addition of retinoic acid
(Figure 3.6A). Genomic DNA was harvested from undifferentiated (ESC) and
differentiated cells at different time points post differentiation (D5, D9). We performed
bisulfite sequencing of the ~400 bp Sall4 enhancer region to determine the temporal gain
of DNA methylation at the CpG target site during ESC differentiation. Bisulfite treated
DNA from various samples were processed for multiplex sequencing on a MiSeq
Illumina high throughput platform (Figure 3.7; for details see methods). Based on the
number of reads, the percent methylation for all the samples could be determined with
high confidence (ESCs: 55,809, D5: 95,646 reads, and D9: 75,894). DNA methylation at
the target CpG site on the Sall4 enhancer increases during differentiation and was
measured at 50% on D5 and 75% on D9 post differentiation (Figure 3.6B).
We next examined the gain in DNA methylation using MD-qPCR, and to
minimize biological variability, the same genomic DNA preparation was used for both
MD-qPCR and bisulfite sequencing assays. Genomic DNA from undifferentiated (ESC)
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and differentiated cells (D5, D9) was sequentially treated with CviQI and MspJI
restriction enzymes (Figure 3.6C). CviQI recognition sites (5’-GTAC-3’) flank the target
CpG site and therefore generates DNA fragments in a size range of 0.3-1 kbp thus
improving the template quality for qPCR. For MD-qPCR, we first tried a small dilution
series of genomic DNA template to determine the concentration that gives the Cq in the
range of ~ 22-24 for both MspJI and HpaII cleaved DNA. Based on our results in Figure
3.3B, this range of the Cq are expected to give reliable measurement of DNA
methylation. 6 ng (2000 copies) of genomic DNA from ESCs, D5 and D9 postdifferentiated cells cleaved with HpaII or MspJI was used as template for qPCR. Changes
in Cq were calculated as a proxy for DNA methylation, which was calculated as ΔCq
(Equation 1; see methods). For both MspJI and HpaII, an increase in ΔCq, was observed
which corresponds to an increase in DNA methylation (Figure 3.6D). The determined
values of ΔΔCq, 0.4, 1.1 and 1.67 for 20%, 50% and 75% percent DNA methylation
respectively (Figure 3.3C) closely match the ΔCq values of 0.4, 1.05, 1.74 corresponding
to the percent methylation gain of 20%, 50% and 75% for ESC, D5 and D9 respectively
detected by the bisulfite sequencing at this site. However, for HpaII cleaved DNA, the
ΔCq values of 1.3, .6, .05 for ESC, D5 and D9 respectively corresponding to 40%, ~75%
and ~95% methylation from Figure 3.3C. Comparing these estimates to the
measurements obtained from the bisulphite sequencing, there is more than 20% error in
the detection of DNA methylation by HpaII-coupled MD-qPCR. This data confirm that
MD-qPCR using MspJI can reliably detect dynamic gains in DNA methylation at in vivo
targets and can be used to measure changes in DNA methylation at single sites with the
use of appropriate standards.
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Compared to HpaII, which cuts at CpG dinucleotides in a 4 bp recognition site, MspJI
recognizes nearly all methylated cytosines, because it is more promiscuous in its
specificity. In regulatory regions of genome with low to intermediate CpG content, HpaII
sites are rare. Given, DNA methylation at various CpG sites is stochastic, methylation at
the HpaII sites may not represent the earliest methylation events in these regions. We
tested this by measuring the DNA methylation in a region of the Oct4 proximal enhancer
containing 3 CpG sites one of which is a HpaII recognition site. During ESC
differentiation, the enhancer of the pluripotency gene Oct4 is methylated (224). We used
HpaII- and MspJI-coupled MD-qPCR to examine the change in DNA methylation in
ESCs, D5 and D9 post differentiation. Fold change in Cq represent change in DNA
methylation from undifferentiated (ESC) to differentiated state. Whereas for MspJIcoupled MD-qPCR the fold change in Cq values shows a sequential increase during
differentiation, there was no significant fold change for the HpaII-coupled MD-qPCR
(Figure 3.6E). We determined the methylation level of each CpG in the Oct4 proximal
enhancer using bisulfite sequencing. The data show that the HpaII site gains a maximum
of 25% DNA methylation by D9 post differentiation (Figure 3.6F). This methylation
level is too low to be detected by HpaII-coupled MD-qPCR. The other two CpG sites,
which gain up to 85% methylation (Figure 3.6F), can be recognized by MspJI, thus easily
reported by the MD-qPCR. These data strongly support MspJI as an enzyme of choice to
detect DNA methylation at low CpG content regions.
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Figure 3.6: Accurate determination of DNA methylation changes at the Sall4 enhancer using MspJI
coupled MD-qPCR.
(A) Schematic representation of ESC differentiation by LIF withdrawal and addition of retinoic acid (RA)
at day three post-induction of differentiation (D3). The time points used are indicated by day (ESC =
Undifferentiated, D3, D5, D9 = days post differentiation). (B) DNA methylation analysis of the single CpG
site in the Sall4 enhancer by bisulfite sequencing. Average and standard deviation of two biological
replicates is shown. (C) Illustration of sample treatment for MD-qPCR analysis of a genomic target using
MspJI or HpaII coupled MD-qPCR. Open circles represent unmethylated CpG, and closed circles
methylated CpG. The purified genomic DNA was digested sequentially by CviQI and MspJI or HpaII
enzymes and the target region was amplified by qPCR. Arrows adjacent to DNA represent primer-binding
sites. (D) DNA methylation analysis of the Sall4 enhancer by MspJI-coupled MD-qPCR shows a gain in
DNA methylation. ΔCq, is the Cq of MspJI cleaved DNA normalized to that of the CviQI control (Equation
1). (E) DNA methylation analysis of the Oct4 proximal enhancer by MspJI or HpaII -coupled MD-qPCR.
Fold change in Cq, is calculated relative to Cq of the undifferentiated (ESC) state [2(Cq D5/D9 - CqESC)]. (F)
DNA methylation analysis of the CpG sites in the Oct4 enhancer by bisulfite sequencing. Average and
standard deviation of two biological replicates is shown. For MD-qPCR, averages ± the standard deviation
are shown (n ≥ 8).
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Figure 3.7: Barcoding of the Sall4 amplicon using TruSeq i5 and i7 adaptor primers for highthroughput sequencing.
Schematic for preparation of indexed amplicons for bisulfite sequencing. The region of interest (black line),
amplified by PCR, is used as a template for barcoding. The first PCR introduces a universal adaptor (blue
and red) to the ends of the amplicon. These adaptor primers used for first PCR consist of a ~30 bp sequence
complementary to the region of interest (black arrows), followed by a ~12 bp linker sequence (grey box),
and a ~20 bp (Truseq Back) forward and reverse adaptors (red and blue boxes). The second PCR adds the
unique identifier and the sequencing primers for high throughput sequencing. The primers used for second
PCR consist of a ~20 bp sequence complementary to the Truseq Back adaptor sequence (red and blue
arrows), followed by a unique index sequence of 8 bp (purple box), and a ~25 bp (Truseq Front) forward
and reverse sequencing primers (green and yellow boxes). The color-coded sequences are listed in Table
3.1.
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3.6 Discussion
Studies showing that differential DNA methylation is associated with the presence
and prognosis of disease states support the need to accurately and quickly detect
abnormal changes in DNA methylation (271-273). Due to methylation sensitivity and
sequence specificity of restriction enzymes, DNA methylation at specific genomic sites
can be examined conveniently by MDR especially when coupled to quantitative PCR
(MD-qPCR). Several strategies have been employed to improve the detectability of DNA
methylation using MD-qPCR that include MethylScreen and EpiteckII (195). These
techniques use combination of methylation dependent and methylation sensitive enzymes
to reduce background noise and report on the density of DNA methylation. Other
methylation dependent qPCR techniques such MethylLight does not use restriction
enzymes, instead uses Dual labelled Taqman probe which can specifically bind to
methylated or unmethylated sequence (261). This technique is derived from the
methylation specific PCR (MSP) method, which uses specific primer design for selective
amplification of methylated and unmethylated regions (196). In this study, we show that
the use of methylation-dependent enzyme MspJI expands the possibilities for MD-qPCR
to be used for detection of DNA methylation gains. This modified method has several
advantages: 1) it is a simple and cost-effective technique that reproducibly permits an
accurate determination of DNA methylation; 2) it is equally applicable to in vitro and in
vivo substrates; and 3) compared to HpaII, which has a specific four-base recognition
sequence, use of MspJI increases the range of target sites that can be assayed by MDqPCR. Compared to MethylScreen, which requires two restriction enzymes and four
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reactions and a complex data analysis, this method involves one restriction enzyme and
two reactions and a simpler data analysis.
Our analysis with in vitro methylated DNA demonstrates that under limiting DNA
concentrations, small gains of DNA methylation were resolved when the substrate was
cleaved with MspJI compared to that with HpaII and the limit of detection of methylation
was four fold higher using MspJI-coupled MD-qPCR. We next examined the utility of
using MspJI with MD-qPCR for the detection and measurement of gain of DNA
methylation in vivo during differentiation of ESCs. We measured the gain of DNA
methylation at a CpG site in the Sall4 enhancer during ESC differentiation using bisulfite
sequencing and MD-qPCR. Using the change in Cq values in Figure 3.3C as a standard
for percent DNA methylation, the ΔCq in Figure 3.6D suggests that post differentiation,
DNA methylation is potentially increased to ~50% on D5 and ~75% on D9 at the Sall4
enhancer CpG site. Strikingly, the values for MD-qPCR are consistent with the increase
in DNA methylation evaluated by bisulfite sequencing. These data suggest that MspJI is
suitable to quantify gain of DNA methylation in vivo with the use of appropriate
standards. The data from the standard curve suggests that a minimum of 10% change in
DNA methylation can be reliably detected with DNA concentration higher than or equal
to12 fM (CpG sites). Further, MspJI allows the detection of methylation at nearly any
cytosine residue compared to HpaII, which has a four-base pair recognition sequence.
This is demonstrated by our data showing that DNA methylation gain at the Oct4
proximal enhancer could be detected using MspJI- and not HpaII-coupled MD-qPCR.
However, since MspJI cleaves DNA ~15 bp away from its recognition site, DNA
methylation at multiple CpGs in close proximity may not be detected individually. MspJI
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also has the ability to cleave at hydroxymethylated sites allowing the use of MD-qPCR to
monitor hydroxymethylation states, and addition of glycosylation would allow for the
distinction between methylation and hydroxymethylation (274). Although MspJI is
incapable of distinguishing between methylation and hydroxymethylation, our data in
Figure 3.6 are not affected by this property. This is because we are analyzing the regions
in the genome that were previously shown to be repressed by DNA methylation upon
ESC differentiation (224, 267).
Previous studies have used McrBC combined with qPCR to measure DNA
methylation at imprinted loci and repeat elements (263, 275). McrBC recognizes two
methylated cytosines residues in (G/A)mC site, 50 -3000 bp apart and cuts approximately
30 bp from either of the two half sites (199). Therefore, the cleavage efficiency of
McrBC is influenced by the density of DNA methylation around the target site, thus
affecting the accuracy of the measurement of DNA methylation at the target site (195).
This limits the utility of McrBC to measure methylation only at CpG rich regions like
repetitive elements and imprinted loci, which are heavily methylated. Changes in DNA
methylation at imprinted loci and high CpG rich tissue specific DMRs has been indeed
reported using McrBC (263). In contrast, MspJI recognizes one methylated cytosine in
CNNR sites and cuts about 15 bps 3’end of the site, thus specifically reporting on the

m

methylation of the target site (198). This allows the enzyme to be equally efficient at CpG
rich or CpG poor regions independent of the methylation status of the flanking region.
Moreover, MspJI recognizes each methylated cytosine individually in a CpG site on the
double stranded DNA, thus making it feasible to determine hemi- versus full methylation
using alternative primer design in quantitative PCR. This is because the fragmentation of
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the DNA with hemi- and fully methylated sites will be different (230). Whereas at hemimethylated CpG the DNA will be cut only on one side (3’ end) of the site, MspJI will cut
on both sides at a fully methylated CpG releasing a short ~32mer fragment. A primer
centered on the recognition site paired with either flanking primers will report on the
methylation status of the individual cytosines in CpG site. Other members of the MspJI
family including FspEI may also be used for these studies; however, FspEI recognizes
CmC sites thereby restricting its potential (260).
Given its simplicity, this method can be broadly employed in experiments
investigating the relationship between the change in 5mC levels at specific sites and cell
states or the influence of 5mC on the interaction of DNA binding factors with their target
site. We have previously used this method to monitor establishment of DNA methylation
by Dnmt3a at the enhancers of pluripotency genes (267) and confirmed those data using
bisulfite sequencing. The property of MspJI to recognize a single methylation event on a
CpG site makes it an enzyme of choice to detect the asymmetric methylation activity of
de novo DNA methyltransferase Dnmt3a (276). DNA methylation of cell-type specific
enhancers strongly correlates with repression of the associated gene and is implicated in
diseased cell state (209-212). Similarly, loss of tumor-suppressor gene expression is
accompanied with aberrant gain of DNA methylation at their promoters that can
potentially be detected using this method (277-279). Particularly, using MspJI in this
method will support the detection of DNA methylation from limited amounts of patient
tissue available for these assays, thus improving the diagnostic potential of MD-qPCR.
In addition, DNA methylation also affects binding of transcription regulators to their
recognition sequences (260, 280). A high-throughput analysis of the impact of
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methylation on DNA binding of transcription factors shows that among the factors that
bound to methylated motifs many were classified as oncogenes, tumor suppressors, and
those required for development (208). Determination of DNA methylation changes at
these sites by MspJI coupled to MD-qPCR can be informative about the potential binding
of transcription factors. We propose that this method will be useful for the detection of
changes in methylation at low CpG content regions, especially when detection is limited
by substrate availability.
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CHAPTER 4: PERSPECTIVES

4.1 Outlook on the regulation of targeting DNA methylation
4.1.1 Conclusions
Site-specific DNA methylation by the Dnmt3 family of enzymes can be
influenced by their catalytic properties and by interaction with other proteins and posttranslational modifications on chromatin (147, 148, 214). We delineated a novel
mechanism in ESCs wherein the activity of Dnmt3a at the enhancers of pluripotency
genes is an important factor in their repression post-differentiation. Dnmt3a activity is
activated by H3K4me1 demethylation by Lsd1, which generates a H3K4me0 tail that
interacts with the ADD domain of Dnmt3a (267). This provides an in vivo mechanism by
which H3K4 demethylation acts as an epigenetic switch to regulate dynamic gains of
DNA methylation at specific locations in the genome. This process has a two-fold
relevance for gene regulation: 1) a mechanism by which H3K4 demethylation is able to
directly regulate the specificity of DNA methyltransferases, and 2) a mechanism where
DNA methylation plays an integral role for establishing and maintaining both enhancer
and gene repression. The importance of DNA methylation in repression is underscored by
several studies which show that targeting DNA methylation to promoters with dCas9 or
TALE fused to a DNA methyltransferase is able to induce gene repression (281-284).
This suggests that gain of DNA methylation is a crucial step in the silencing of regulatory
elements and stable gene repression.
We have used the enhancers for six pluripotency genes as representatives of all
pluripotency gene enhancers to evaluate the potential for Dnmt3a/Lsd1/Mi2-NuRD
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mediated enhancer silencing. The next step will be to determine if this is a global
mechanism affecting enhancer silencing and gene repression or if it isolated to a subset of
pluripotency genes only. The potential for a broad impact of such a mechanism is
supported by data showing that ~1,700 enhancers in ESCs have co-occupancy of Lsd1
with Oct4/Sox2/Nanog/Mediator and lose H3K4me1 upon differentiation (51). We could
investigate the broadness of this mechanism by employing genome-wide sequencing
techniques to track changes in histone modifications, DNA methylation, and gene
expression. These data could support the role of the mechanism we discovered to silence
enhancers of pluripotency genes as a cohort and provide precedent for its applicability in
general enhancer silencing.
4.1.2 Role for the ADD domain in modulating Dnmt3b catalytic activity
A key question in the field is to what extent the chromatin binding domains of the
Dnmt3 proteins affect catalytic activity and target specificity. Our previous study
elucidated the role of the chromatin binding ADD domain in site-specific regulation of
DNA methylation by Dnmt3a, which is supported by the previously published
biochemical data (168, 267). Whereas the PWWP domain of Dnmt3b has been implicated
in mediating gene body DNA methylation through its interaction with histone H3K36
methylation, the role of its ADD domain in regulating catalytic activity remains to be
fully elucidated (163, 285, 286). Interaction studies using peptide arrays have shown that
the ADD domain of Dnmt3b also binds preferably to unmethylated histone H3K4 (225).
Examination of a sequence alignment of Dnmt3a and Dnmt3b show differences in key
regions that regulate the activity of the Dnmt3a ADD domain and therefore could affect
the activity of the Dnmt3b ADD domain (168). Further, the linker region of Dnmt3b is
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shorter and lacks proline residues present in Dnmt3a, which may affect the function of
the ADD domain of Dnmt3b.
Given that Dnmt3a and Dnmt3b have both unique and redundant targets, we
postulate a critical role of the ADD domain of Dnmt3b at regulating its specific activity
towards either or both types of targets. In vitro experiments to determine Dnmt3b activity
in the presence and absence of H3K4 unmodified or modified peptides would reveal the
potential role of the Dnmt3b ADD domain in regulation of its activity. Further, sitedirected mutagenesis of the linker region of Dnmt3b could be performed to test its effect
on the function of the ADD domain and on catalytic activity.
The focus of many of the aforementioned analyses is to determine the impact of
either the ADD domain or the PWWP domain on Dnmt3 activity. However, it is not
known if these domains have a synergistic, exclusive, or additive effect on the activity of
Dnmt3a and/or Dnmt3b. In proteins with tandem chromatin-interacting domains, each
domain is able recognize specific histone modification and thereby regulate activity by
reading combinations of histone modifications (287, 288). A computational modeling
approach supports the hypothesis that the PWWP and ADD domain could bind to the
same histone tail in tandem within spatial constraints (289). The impact of these tandem
readers together on catalytic activity of Dnmt3a and Dnmt3b is unknown and could be
determined by in vitro studies. These investigations into the tandem reader domains of
Dnmt3 enzymes would help elucidate how Dnmt3a and Dnmt3b read the histone code
and how that code affects DNA methyltransferase activity. This would significantly
advance the field because the data could explain the underlying binding and/or activity
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preferences of Dnmt3a and Dnmt3b, which would be critical insights that inform their
spatial and temporal specificity.
4.1.3 Regulation of DNA methylation at pluripotency gene enhancers in F9 cells by
H3K4 demethylation
One important question arising from our study is that of the commonality of the
proposed mechanism. The pluripotency genes are expressed transiently in early
development during the proliferation and migration of PGCs, which become mature germ
cells (290-292). Failure to repress the pluripotency genes in these cells at the proper time
during this process has been related to increased rates of testicular teratoma (293). The
Dnmt3a/Lsd1/Mi2-NuRD mechanism may also play a critical role for pluripotency gene
repression in this context. This could be tested by using embryonic carcinoma (F9) cells
as a model system, as they have a similar expression profile to PGCs during early germ
cell differentiation (294, 295).
We have performed preliminary experiments with F9 cells and found that the
pluripotency gene enhancers fail to gain DNA methylation post-induction of
differentiation. Both Dnmt3a and Lsd1 are expressed in F9 cells, which leaves open the
possibility that the Dnmt3a/Lsd1/Mi2-NuRD mechanism is dysregulated in F9 cells. One
possible reason for these defects may be the retention of active histone modifications,
such as H3K4me1 or H3K27ac. This could be further explored by using inhibitors against
p300 that would be permissive to demethylation, or by transfecting with dCas9-Lsd1 or
dCas9-Dnmt3a targeted to each pluripotency gene enhancer. Alternatively, loss of active
modifications and gain of a repressive histone modifications may be sufficient to mediate
pluripotency gene repression in F9 cells. These experiments using F9 cells could support
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the possibility that Dnmt3a is regulated at pluripotency gene enhancers during the
establishment of PGCs.
4.1.4 Regulation of DNA methylation by H3K4 demethylation at the enhancers of
other developmental genes
Another key extension would examine if a similar mechanism occurs at the
enhancers of developmental genes that are repressed during differentiation of other
progenitor cells. Recent publications have indicated the role of Lsd1 and Dnmt3a in the
fidelity of hematopoietic stem cells (HSCs) to exit multipotency, suggesting a potential
role for our mechanism during HSC differentiation (251, 252, 296). A recent publication
indicated that HSCs with the R882H dominant negative Dnmt3a mutant displayed
hypomethylated regions that are enriched for the enhancer mark H3K4me1 and that these
regions were also hypomethylated in cells post-differentiation of those HSCs (297). A
study examining if the demethylation of H3K4me1 at HSC-specific enhancers during
differentiation would determine if demethylation is acting as the definitive epigenetic
switch to result in Dnmt3a derived DNA methylation.
The relevance of H3K4me1 demethylation in regulating DNA methylation at the
enhancers of HSCs by Dnmt3a could be determined with an experimental design and
methods similar to those proposed for the F9 study. Given that both Dnmt3a and Lsd1 are
necessary for HSC differentiation, it will be important to test if the enhancers of HSC
specific genes gain DNA methylation post-induction of differentiation. It is also
necessary to perform ChIP against H3K27ac and H3K4me1 to determine if those
enhancers undergo deacetylation and demethylation during differentiation. Depending on
these results, the use of Lsd1 or HAT inhibitors could test if the mechanism we found in
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ESCs also occurs in HSCs. Together, these experiments could define a mechanistic basis
for the biological necessity of Dnmt3a and Lsd1 in HSC differentiation.
Broadly, the prevalence of H3K4 demethylation to regulate DNA methylation at
cell specific enhancers during differentiation could be determined by using other
multipotent stem cells as model systems. However, the mechanisms that coordinate the
activity at enhancers with their respective promoters during gene repression will require
further investigation. Thus, these studies would help determine the pervasiveness of our
mechanism, provide an additional framework for regulation of the de novo DNA
methyltransferases, and assess their impact on cell identity.
4.1.5 A potential role of chromatin architecture in mediating regulatory element and
gene repression mechanisms
Chromatin organization is a critical factor in mediating gene expression- multiple
studies and techniques support that enhancers interact with promoters in a looped
topology at expressed genes (69, 70, 298). Many proteins and complexes can mediate the
formation of loops between enhancers and promoters (30, 299, 300). Enhancer-promoter
looping by mediator and cohesion promotes gene activation and expression by linking coactivators at the enhancer with the core transcriptional apparatus at the promoter (301303). These loops have been found to be tissue specific, following tissue specific
enhancer activity and gene expression (304). In the case of the enhancers of pluripotency
genes, enhancer-promoter loops formed by the mediator and cohesin complexes are
present in undifferentiated cells but absent in MEFs, a differentiated cell type (52, 305,
306). These analyses used different cell types for comparison, which means that the
dynamic changes of enhancer-promoter loops during gene repression remain unclear.
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The relationship between the kinetics of enhancer-promoter loop detachment and
gene repression will address the fundamental issue of coordination of gene elements
during repression. Looped DNA architectures mediate various functions outside of gene
activation, ranging from loops including insulator elements for repression to mediating
catalytic activity of DNA modifying enzymes (307-311). A recent study that induced loss
of H3K4 methylation and H3K27 acetylation at enhancers with a dCas9-Lsd1 fusion
protein did not result in de-looping of the enhancer and promoter (312). This suggests
that loss of active chromatin modifications does not incur loss of a looped architecture.
These data also raise the possibility that enhancer-promoter loops could play a role in
gene repression as a mechanism that spatially and temporally localizes regions of the
genome and proteins. It would be interesting to determine if the looped topology is
necessary for stable, coordinated repression of enhancers and their cognate promoters.
Further, evaluating the kinetics of loop detachment and the potential impact of the loops
in synchronizing the formation of a silencing epigenetic landscape at regulatory elements
would represent a novel and significant insight into the mechanisms of gene repression.
To test our hypothesis that enhancer-promoter looping is critical for coordinating
pluripotency gene repression, we followed loop detachment during differentiation by
performing ChIP against the core subunit Med1, which acted as a proxy for mediator and
looping. Using six pluripotency gene enhancers, we found that Med1 has greatest
enrichment in ESCs but is retained up to D5 post-induction of differentiation at ~50% or
greater of ESC levels, after which it is ~5% of ESC levels at D7 (Figure 4.1A). During
this time frame pluripotency genes are repressed, and DNA methylation is gained starting
at D5 (267). This suggests that enhancer-promoter looping persists during the initial
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stages of repression occurring over differentiation. To investigate the potential role of
looping in repression, we generated cell lines with shRNA against the mediator subunit
Med12, or GFP as a control, and confirmed Med12 knockdown by RT-qPCR and
Western blot (Figure 4.1B). We next examined the repression profiles of a battery of
eight pluripotency genes and discovered that there was incomplete repression of these
genes in Med12 knockdown cells versus the control shGFP cells (Figure 4.1C).
Moreover, knockdown of Med12 did not result in defects of Dnmt3a or Dnmt3b
expression, nor did it prevent the activation of the germ-layer specific genes (Figure 4.1D
and 4.1E). Our preliminary investigation also examined the gain of DNA methylation of
the enhancers of six pluripotency genes, which in the shMed12 cells failed to gain DNA
methylation during differentiation as compared to the shGFP control cells (Figure 4.1F).
Interestingly, bisulfite-sequencing of the promoters of the same genes indicated smaller
defects in gains of DNA methylation during differentiation (Figure 4.1G). These
preliminary data support a role for enhancer-promoter looping in mediating pluripotency
gene repression, where stable enhancer silencing is more strongly effected by looping
than the promoter.
Based on our preliminary data, several other questions should be addressed to test
our hypothesis that looping is crucial for gene repression. Performing the same
experiments as above with cells knocked down for a cohesion subunit would further
substantiate the role of chromatin topology in affecting gene repression. The knockdown
cell lines could be differentiated to monitor the loss of active histone modifications and
the gain of repressive epigenetic modifications at regulatory elements. Any observed
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differences over differentiation could provide insight into the effect of loss of looping on
changes in epigenetic modifications and gene repression.
Our experimental design would not only test the role of enhancer-promoter
conformation on gene repression, but also give crucial insight into how the diverse
repressive mechanisms acting at enhancers and promoters synergize to effect complete
gene repression. It may be possible to tease apart the relative contributions and
cooperativity of these separate mechanisms in gene repression by using inhibitor
treatments in mediator or cohesion knockdown cell lines. By performing analysis of
histone and DNA modifications in this context, we would gain insight into the
interdependence or independence of the repressive mechanisms that are prevalent at the
enhancer and promoter. These would be novel findings that would demonstrate the
process by which different repressive mechanisms coordinate for regulatory element
silencing and complete gene repression.
A hallmark of cancer genomes is aberrant DNA methylation patterns that impact
pathways effecting cell identity (120, 258, 279). One in three cancer lines maintained by
the Cancer Genome Anatomy Project show activation of pluripotency genes, suggesting
that their re-activation may potentiate development of a cancerous cell state (313).
Expression of several core pluripotency factors has been linked to resistance against
chemical and radiological therapies, and enhances the risk of metastasis (314-318). These
highly durable and proliferative cancer cells, referred to as cancer stem cells, undergo
self-renewal and override apoptotic pathways due in part to the expression of the
pluripotency genes (318-324). Analysis of enhancer-promoter loop mediated gene
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repression may provide new processes that contribute to the aberrant expression of
pluripotency genes in cancer cells and shed light on therapeutic strategies and targets.

113

Figure 4.1: Persistence of enhancer-promoter looping helps complete pluripotency gene repression.
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(A) Med1, a mediator subunit, is found at pluripotency gene enhancers up to D5 post differentiation using
ChIP with qPCR targeted to pluripotency gene enhancers. These genes are repressed prior to complete
dissociation of Mediator, as suggested by the presence of Med1 after initiation of gene repression by D5
(B) Expression of shRNA target Med12 is decreased in ESCs of knockdown lines as detected by RT-qPCR
and Western blot compare to shGFP controls. (C) RT-qPCR in Med12 knockdown lines show disrupted
basal expression of pluripotency genes, as well as incomplete repression of pluripotency genes during
differentiation as compared to a shGFP control line. (D) Expression of Dnmt3 family of genes is not
reduced by shRNA treatments as performed by RT-qPCR. (E) RT-qPCR done for germ layer genes reveals
expression of those genes upon shGFP and shMed12 cell line differentiation. (F) Analysis of DNA
methylation by bisulfite sequencing at enhancers of the pluripotency genes reveals defects in gain of DNA
methylation in the shMed12 cell line relative to shGFP cells over differentiation. (G) Bisulfite sequencing
of the promoters of the pluripotency genes indicated that differentiated shMed12 have limited defects in
gain of DNA methylation. For RT-qPCR analysis, all data are normalized to ESC for shGFP cell lines such
that the value is set to 0 for two biological replicates. For ChIP and RT-qPCR, average and standard
deviation of triplicate analysis shown. For bisulfite sequencing, the average percent DNA methylation for
all CpG in the sequence is shown; each average is based on at least 1000 reads from one biological
replicate.
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4.2 Applications of MD-qPCR
4.2.1 Conclusions
Methylation sensitive restriction enzymes are employed in detecting DNA
methylation by methods that rely on Southern blot, PCR, or qPCR (190, 325).
Conversely, the methylation dependent enzymes have been rarely used to quantify DNA
methylation- only McrBC has been coupled to qPCR and with its own limitations (195,
199, 263). The discovery of proteins such as MspJI has provided a new family of
methylation dependent enzymes that can be used to monitor DNA methylation (198). We
developed a novel method for analyzing differences in DNA methylation at specific
genomic sites using MspJI to cleave methylated DNA, which serves as the template for
qPCR (326). This method works around limitations imposed by methylation sensitive
enzymes, in this case HpaII, that have reduced detection ranges for small differences in
DNA methylation. We found that MspJI had greater accuracy over a wider range of
template DNA concentrations compared to HpaII, and that MspJI also was more accurate
at analyzing in vivo genomic targets that gain DNA methylation.
This method could correlate DNA methylation levels at specific sites with cell
identity and disease states alone, or as an orthogonal technique. Aberrant DNA
methylation of specific genomic regions has already been established and used as a
biomarker for multiple disease states (327, 328). Therefore, MD-qPCR could be used to
evaluate DNA methylation biomarkers across multiple sites in clinical samples, and do so
with accuracy even when only low amounts of DNA are available per reaction.
Additionally, our method also has the potential to correlate DNA methylation with the
presence of DNA binding proteins. This is of mechanistic interest since transcription
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factors exhibit preferences for binding to sequences with specific DNA methylation states
(280, 329). Thus, MD-qPCR could also be used to help define the level of DNA
methylation at a sequence recognized by a DNA binding factor and its influence on
binding of that protein.
4.2.2 Adaptation of MD-qPCR to evaluate strand-specific cytosine modifications
MD-qPCR takes advantage of several catalytic properties of MspJI to detect modification
of cytosine, including strand-specific recognition of methylation and hydroxymethylation
(198, 230). This effectively means that MD-qPCR could employ alternative primer
positions to discriminate if cytosine modification(s) are present on either DNA strand or
both. This would provide insight into the distribution of de novo DNA methylation or
could infer if the DNA carries pre- or post-replicative DNA methylation patterns.
Similarly, it could differentiate between methylation and hydroxymethylation of cytosine
by introducing a DNA glucosyltransferase enzyme during sample preparation that would
protect hydroxymethylated DNA from MspJI cleavage (230, 274). The use of MspJI
cleavage to monitor hydroxymethylation could be tested using the same artificial
substrate and experimental design as before, where the methylated cytosine is
hydroxymethylated instead. Moreover, this adaptation could be used, for example, to
monitor regulatory element activation by TET-mediated oxidation of DNA methylation
(330, 331). Genomic DNA at these enhancers over differentiation present ideal targets to
test the use of this design in monitoring hydroxymethylation of an in vivo target. The
purified gDNA needs to be treated with the glucosyltransferase, then cleaved with MspJI
or HpaII prior to qPCR and the results compared to pyrosequencing, which discriminates
between methylation and hydroxymethylation. Further, inclusion of a glucosyltransferase
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could determine if a DNA binding protein preferred a specific modification state of
cytosine, as observed for UHRF2 and MBD4 (332, 333). These catalytic properties make
MspJI a highly flexible enzyme to examine cytosine modifications at specific sites and
increase the potential versatility of the MD-qPCR assay.
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Research Summary
As a graduate student under Dr. Humaira Gowher at Purdue University’s
Department of Biochemistry, one of my research projects was to determine a potential
mechanism underlying the spatiotemporal specificity of DNA methylation, an
epigenetic mark critical for maintaining cell identity that is associated with gene
repression and deposited de novo by Dnmt3a and Dnmt3b. I published in Nucleic Acids
Research (2016) that local histone demethylation and deacetylation by the Lsd1Mi2/NuRD complex permits the specific interaction of the ADD domain of Dnmt3a
with the unmethylated H3 tail at lysine 4 (H3K4), resulting in the catalytic activation of
Dnmt3a and site-specific methylation at pluripotency gene enhancers. This study
provided a novel and crucial mechanistic insight into the epigenetic regulation of DNA
methyltransferases.
To evaluate the gain of DNA methylation at enhancers, I refined the DNA
methylation dependent quantitative PCR method by coupling it with the restriction
enzyme MspJI that cleaves methylated DNA. This work was published in Analytical
Biochemistry (2017), and I showed that MspJI substantially improved the detection
limits for gains of DNA methylation as compared to HpaII, which is inhibited by DNA
methylation. This broadly applicable method can
now be employed to investigate the relationship between changes in DNA methylation
levels at specific sites within the genome during cell differentiation.
In addition, I collaborated with other members of Gowher lab and contributed
to other projects. I am a co-author on a 2016 publication in Biochemistry, which
characterized the intrinsic catalytic properties of the Dnmt3b catalytic domain as
compared to the Dnmt3a catalytic domain. Our results demonstrated important
mechanistic differences between Dnmt3b and Dnmt3a catalytic domains despite high
homology. This study delineates these differences that may have implications for the
distinct biological roles of Dnmt3a and Dnmt3b.
In total, my research experience has provided me with in-depth experimental,
deductive reasoning, literature proficiency, and problem-solving skills in tackling
challenging research questions proposed with Dr. Gowher.
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